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Abstract 
Uncaria tomentosa (Rubiaceae), a medicinal plant native to Peru, has been 
traditionally used for centuries as a treatment for a wide variety of diseases, as well as to 
maintain health. It grows primarily in the Amazon rainforest and throughout South and 
Central America. U. tomentosa extracts have been demonstrated to have anti-oxidant, 
anti-apoptotic, anti-inflammatory and anti-cancer properties. The goal of this study was to 
examine Uncaria tomentosa in both in vitro and in vivo models in order to evaluate its 
potential anti-cancer activity using the B16-BL6 mouse melanoma and 4T1 mouse breast 
cancer cell lines. Both ethanol and PBS extracts of U. tomentosa were prepared and used 
to measure the effects on cell growth and survival using several different methodologies. 
Treatment of cells with ethanol extracts was much more effective at inhibiting cancer cell 
growth than treatment with PBS extracts in vitro, but no significant differences in the 
cancer inhibitory effects were observed in vivo. The in vitro experiments showed that 
treatment with the U. tomentosa extract significantly inhibited the growth of both B16-
BL6 and 4T1 cell lines. It also inhibited the expression of the Ki-67 proliferation marker 
and promoted cell death as measured by increased DNA fragmentation using TUNEL 
assays in cancer cells. Treatment with the ethanol extract of U. tomentosa caused a 
significant increase in the fraction of apoptotic cells in flow cytometry (i.e. sub G1 
peaks). Furthermore, two animal experiments were performed in order to evaluate the 
effect of U. tomentosa treatment on B16-BL6 cells in C57BL/6 mice. The results of the in 
vivo experiments concluded that treatment with U. tomentosa reduced tumour weight and 
tumour size. Histochemical analysis of the B16-BL6 tumours showed a strong reduction 
in the Ki-67 cell proliferation marker and a small but not significant increase in DNA 
 iv 
 
fragmentation in U. tomentosa-treated mice compared to the control. Further, U. 
tomentosa extracts reduced staining for Factor VIII, a marker for endothelial cells, 
indicating a decrease in angiogenesis in treated mice. Since U. tomentosa has been shown 
to affect immune system function, the infiltration of several different immune cells into 
the tumour was examined. No significant differences in the number of infiltrating T cells 
(including T helper and cytotoxic T cells), B cells, or platelets were found between the 
treated groups and the control. Collectively, the results in this study concluded that U. 
tomentosa has potent anticancer activity that significantly inhibited cancer cell growth 
both in vitro and in vivo. The discovery of new medicinal plants that are effective against 
cancer cells may provide a strategy to develop cancer therapy and requires more 
attention. 
 
 
 
 
 
 
 
 
Keywords:  
Uncaria tomentosa extracts, 4T1 breast cancer cells, B16-BL6 mouse melanoma cells, 
anticancer, apoptosis. 
 v 
 
Acknowledgements 
I would like to offer my special appreciation and thanks to my supervisor Dr. 
Robert Lafrenie who encouraged and directed me throughout my PhD thesis. His 
immense knowledge, insightful discussions, understanding and scientific advice brought 
this work towards a completion. I am deeply thankful to him for the useful comments and 
the valuable remarks that he has provided to me throughout the PhD research studies. 
Without his support and guidance this research would not have been achievable. 
Besides my supervisor, I am also grateful to my dissertation committee members, 
Dr. Kabwe Nkongolo and Dr. Michael Persinger, for the great support. I am thankful to 
Dr. Kabwe Nkongolo for his brilliant comments and helpful suggestions that served me 
well in the research. I also show gratitude for Dr. Michael Persinger who unfortunately 
passed away a few months before the official defense. 
My thanks are extended to my father Dr. Talal Zari and my mother Ahlam Al-
khateeb for continuous encouragement, love, and support throughout the time of my 
research. Special thanks are due to my wife Nujood Kheshaifaty for the endless support 
and continued patience she gave me throughout my research. Finally, I would like to 
thank my lab mates for their useful discussions and continued support. 
 vi 
 
Table of contents 
Abstract …………………………………….……………..…………… ……………...iii 
Acknowledgements ……………………………………………………… …………….v 
Table of Contents ………………………..……………….….……………...…………..vi 
List of Tables……………………………………………………………………..…...…x 
List of Figures ……………………..……………………...…….………........…….…..xii 
Abbreviations ……..………………………………………..…………….……………xvi 
Chapter 1: General Introduction……………………...……….…...….….....…...1 
1.1 Cancer……………….………………………………………………..…….…........…1 
1.2 Breast Cancer …... ………………….…………………………………….….……....4 
1.3 Breast cancer risk factors …….…. ………......……………………….……....…...…6 
1.4 Treatment of breast cancer…………….…………... ……………………………..….9 
1.5 Side effects of some treatments…….. ..……………………………………………..12 
1.6 Importance of medicinal plants……….….. ………………………………….……..13 
1.7 Side effects of some herbs ……………….…………………………………..….…..16 
1.8 Apoptosis………………...…………………………………………………………..17 
1.9 Immune system ………………………..………………………………...…………..21 
1.10 Immune system responses in cancer ……………………………………...………..24 
1.11 Uncaria tomentosa …………………………..………………………………..……29 
1.12 Objectives and Experimental Summary……………...……………………………..35 
Chapter 2: Uncaria tomentosa extracts were examined in vitro to measure the growth 
and survival of cancer cells (B16-BL6 and 4T1) …………………..………........37 
2.1 Introduction………………..…….………………………………………………….37 
 vii 
 
2.2 Materials and Methods………………………….…….……………………………40 
2.2.1 Tissue culture ……………………………………………….……………………..40 
2.2.2 Uncaria tomentosa extracts  ....................................................................................40 
2.2.3 Cell treatments..........................................................................................................41 
2.2.4 MTT assay (Methyl Tetrazolium Blue) ...................................................................42 
2.2.5 Cell Morphology……………….…..........................................................................43 
2.2.6 Fluorescence Immunohistochemistry for Ki-67 protein expression.........................44 
2.2.7 TUNEL assay ………….…………..........................................................................45 
2.2.8 Flow cytometry ........................................................................................................45 
2.2.9 HPLC (High-performance liquid chromatography) ..………..………...……..…....46 
2.3 Results ........................................................................................................................48 
2.3.1 The effect of U. tomentosa extracts on the proliferation of 4T1breast cancer and 
B16-BL6 melanoma cancer………………...…………………..…………....…..48 
2.3.2 Cell morphology……….…………….………………….........................................58 
2.3.3 Inhibition of the proliferation of cancer cells (4T1 and B16-BL6) using Ki-67 
protein expression .................................................................................................70 
2.3.4 Detection of DNA fragmentation in 4T1 cells and B16-BL6 cells treated with U. 
tomentosa extracts.................................................................................................84 
2.3.5 Detection of 4T1 cell accumulation in sub-G1 using flow cytometry ...................102 
2.3.6 HPLC analysis of U. tomentosa extracts and fractions and their effect on cell 
growth……………………………………………………………..….…….......108 
2.4 Discussion .................................................................................................................116 
2.4.1 Identification of Uncaria tomentosa ......................................................................116 
 viii 
 
2.4.2 Anti-proliferation activity of U. tomentosa extracts .............................................118 
2.4.3 Anti-proliferation activity of U. tomentosa extracts using Ki-67 protein expression 
..........................................................................................................................................121 
2.4.4 DNA fragmentation caused by treatment with the U. tomentosa extracts……..…122 
2.4.5 Apoptosis induction by U. tomentosa extract detected using flow cytometry…....124 
Chapter 3 Uncaria tomentosa extracts were examined in vivo to measure the growth 
and survival of B16-BL6 cancer cells…………………………………...….….126 
3.1 Introduction………………..…….………………………………...………………125 
3.2 Materials and Methods………………………….…….………………………..…128 
3.2.1 Uncaria tomentosa extracts  ..................................................................................128 
3.2.2 Animal Experiments …………………………….………..………...……...….…128 
3.2.3 Histochemical analysis of tissue sections……………………………...…………130 
3.2.4.TUNEL staining of histochemical sections……………..…………………..……133 
3.3 Results……………………………………….……………………………………..135 
3.3.1 Examining the anticancer activities and protective effects of U. tomentosa extracts 
on male C57BL/6 mice by measuring body weight, tumour weight, and tumour 
size ......................................................................................................................135 
3.3.2 Histochemical analysis was performed for B16-BL6 tumours………....……..….150 
3.3.3 Immune cell infiltration in B16-Bl6 tumours was studied using several immune 
markers………………………………………………………………………….162 
3.4 Discussion .................................................................................................................181 
3.4.1 The effect of U. tomentosa extract on tumour weight and size in animal models..181 
 ix 
 
3.4.2 B16-BL6 tumours were analyzed using histochemical detection of Ki-67, factor 
VIII, and TUNEL markers…………………………….....……………….…….183 
3.4.3 Immune infiltration into B16-BL6 tumours were studied through immune 
markers….……………………………………………………….……………...185 
Chapter 4: General Conclusions ........................................................................188 
4.1 Cancer and natural products......................................................................................188 
4.2 Uncaria tomentosa extracts.......................................................................................189 
4.3 Comparing the effects of U. tomentosa extracts between in vitro results and in vivo 
results...................................................................................................................190 
4.4 Conclusion.................................................................................................................193 
References ......................................................................................................................195 
 
 
 
  
 x 
 
List of Tables 
Table 3.1 The weight of the mice at sacrifice for experiment 1…....………..….….….138 
Table 3.2 The weight of B16-BL6 tumours at sacrifice for experiment 1 ……..……...138 
Table 3.3 The diameter of B16-BL6 tumours at sacrifice for experiment 1……………138  
Table 3.4 The weight of the mice at sacrifice for experiment 2………………….....….139 
Table 3.5 The weight of B16-BL6 tumour at sacrifice for experiment 2…....…............139  
Table 3.6 The diameter of B16-BL6 tumours at sacrifice for experiment 2……………139  
Table 3.7 The weight of the mice at sacrifice for combined experiments 1 and 2…......140 
Table 3.8 The weight of B16-BL6 tumours at sacrifice for combined experiments 1 and 2 
…………………...…………………………………………………………….…....….140 
Table 3.9 The diameter of B16-BL6 tumours at sacrifice for combined experiments 1 and 
2……………………………………………………………………..……….…140 
Table 3.10 Regression statistics for tumour size as a function of tumour weight 
…………………………………………...………………...…………………………....141 
Table 3.11 The mean and variation in Ki-67 staining intensity for tumours from mice 
treated with U. tomentosa extracts ……………...……..…………………....….153 
Table 3.12 The mean and variation in Factor VIII staining intensity for tumours from 
mice treated with U. tomentosa extracts…………………..………..……..……153 
Table 3.13 The mean and variation in TUNEL staining intensity for tumours from mice 
treated with U. tomentosa extracts…………………………..…………..….…..153 
Table 3.14 Comparison of relative staining intensity for control IgG1 Alexa-488….....171 
Table 3.15 Comparison of relative staining intensity for control IgG2 Alexa-546….…171 
Table 3.16 Comparison of relative staining intensity for control IgG2 Alexa-633…….171 
 xi 
 
Table 3.17 Comparison of relative staining intensity for anti-CD4-Alexa-488….…….174 
Table 3.18 Comparison of relative staining intensity for anti-CD3- Alexa-546……….174 
Table 3.19 Comparison of relative staining intensity for anti-CD8- Alexa-633……….174 
Table 3.20 Comparison of relative staining intensity for anti-PECAM-1-Alexa-488….177 
Table 3.21 Comparison of relative staining intensity for anti-E-selectin-Alexa-546 .....177 
Table 3.22 Comparison of relative staining intensity for anti-ICAM-1-Alexa-633…....177 
Table 3.23 Comparison of relative staining intensity for anti-CD45-Alexa-488……....180  
Table 3.24 Comparison of relative staining intensity for anti-CD19-Alexa-546……....180   
Table 3.25 Comparison of relative staining intensity for anti-integrin αIIb-Alexa-633. 
…………………………………………………………………………………………. 180 
 
 
 xii 
 
List of figures 
Figure 2.1 Effect of U. tomentosa extracted with ethanol on the growth of the 4T1 cell 
line …………………………………………….……………..…………………..50 
Figure 2.2 Effect of U. tomentosa extracted with PBS on the growth of the 4T1 cell 
line……………………………………………………………..…………………52 
Figure 2.3 Inhibition of B16- BL6 cell proliferation treated with U. tomentosa extracted 
with ethanol……………………...……………………………………………….54 
Figure 2.4 Inhibition of B16- BL6 cell proliferation treated with U. tomentosa extracted 
with PBS…………………………………………………..….………………….56 
Figure 2.5 Effect of U. tomentosa ethanol extract on the morphology of the 4T1 cell 
line………………………………...……..……………………………………….60 
Figure 2.6 Effect of U. tomentosa PBS extract on the morphology of the 4T1 cell 
line……………………………...…..…………………………………………….62 
Figure 2.7 Effect of U. tomentosa ethanol extract on the morphology of the B16-BL6 cell 
line………………………………………………………………………...…...…64 
Figure 2.8 Effect of U. tomentosa PBS extract on the morphology of the B16-BL6 cell 
line…………………….………………………………..…..…....……………….67 
Figure 2.9 Effect of U. tomentosa extracted with ethanol on 4T1 cell proliferation …....72 
Figure 2.10 Effect of U. tomentosa extracted with ethanol on 4T1 cell proliferation…...74 
Figure 2.11 Effect of U. tomentosa extracted with PBS on 4T1 cell proliferation........…76 
Figure 2.12 Effect of U. tomentosa extracted with PBS on 4T1 cell proliferation............78 
 
 xiii 
 
 
Figure 2.13 Effect of U. tomentosa extracted with ethanol on B16-BL6 cell 
proliferation………………………………...………………………….……..…..80 
Figure 2.14 Effect of U. tomentosa extracted with PBS on B16-BL6 cell 
proliferation………………………………..……………………………………..82 
Figure 2.15 Detection of DNA fragmentation in 4T1 cells treated with U. tomentosa 
extracted with ethanol using the TUNEL assay for 24 hours…………………....86 
Figure 2.16 Detection of DNA fragmentation in 4T1 cells treated with U. tomentosa 
extracted with ethanol using the TUNEL assay for 48 hours……………………88 
Figure 2.17 Detection of DNA fragmentation in 4T1 cells treated with U. tomentosa 
extracted with PBS using the TUNEL assay for 24 hours…………………….…90 
Figure 2.18 Detection of DNA fragmentation in 4T1 cells treated with U. tomentosa 
extracted with PBS using the TUNAL assay for 48 hours……………...…….…92 
Figure 2.19 Detection of cell death in B16-BL6 cells treated with U. tomentosa extracted 
with ethanol using the TUNEL assay for 24 hours…………………………...….94 
Figure 2.20 Detection of cell death in B16-BL6 cells treated with U. tomentosa extracted 
with ethanol using the TUNAL assay for 72 hours………………………..…….96 
Figure 2.21 Detection of cell death in B16-BL6 cells treated with U. tomentosa extracted 
with PBS using the TUNEL assay for 24 hours………..…………….…...……..98 
Figure 2.22 Detection of cell death in B16-BL6 cells treated with U. tomentosa extracted 
with PBS using the TUNEL assay for 72 hours………………...…...…………100 
Figure 2.23 Effect of U. tomentosa extracted with ethanol on cell cycle profiles (sub-G1 
peaks) in 4T1 cells………………...………………………………..………..…104 
 xiv 
 
 
Figure 2.24 Effect of U. tomentosa extracted with PBS on cell cycle profiles (sub-G1 
peaks) in 4T1 cells……………………...…………………………..……..……106 
Figure 2.25 Analysis of U. tomentosa extracts using HPLC……………..….…….…...110 
Figure 2.26 Analysis of U. tomentosa extracts fractionated by PVPP column 
chromatography using HPLC…………………...…………………….………..112 
Figure 2.27 Effect of U. tomentosa fractions on cell proliferation……………..……....114 
Figure 3.28 Body weight was evaluated following the use of U. tomentosa treatment...142 
Figure 3.29 Tumour weight was evaluated following the use of U. tomentosa 
treatment……………………………………………………………..………....144 
Figure 3.30 Tumour size was evaluated following the use of U. tomentosa treatment...146 
Figure 3.31 The correlation between tumour weight and tumour size in C57BL/6 
mice……………………………………………………………………………..148 
Figure 3.32 The presence of Ki67-positive cells was detected in histochemical sections 
from mice treated with U. tomentosa extracts……………………….......……..154 
Figure 3.33 The relative level of Ki67-positive cells was decreased in histochemical 
sections from mice treated with U. tomentosa extracts……………....…..……156 
Figure 3.34 The relative level of Factor VIII-positive cells was significantly decreased in 
histochemical sections from mice treated with U. tomentosa extracts....……...158 
Figure 3.35 The relative level of TUNEL-positive stained cells in histochemical sections 
from mice treated with U. tomentosa extracts was not significantly altered......160 
Figure 3.36 Scoring relative staining intensity of immune cell infiltration for the three 
fluorochromes used for analysis………………………………………………..167 
 xv 
 
Figure 3.37 B16-Bl6 tumours were stained with control normal mouse IgG1, normal 
mouse IgG2b, and normal rat IgG2a……………………...…………………….169 
Figure 3.38 B16-Bl6 tumours were stained for T cell markers CD4, CD3, and CD8….172 
Figure 3.39 B16-Bl6 tumours were evaluated through PECAM -1, E - selectin, and 
ICAM – 1……………………………………………………………………….175 
Figure 3.40 B16-Bl6 tumours were evaluated through CD45, CD19, and Integrin 
αllb……………………………………………………………………………...178 
 
 xvi 
 
Abbreviations 
ATCC  American Type Culture Collection 
Bcl- 2  B-cell lymphoma 2 
BHT   butylated hydroxytoluene 
BHA   butylated hydroxylanisole 
BRCA1  Breast cancer type1 susceptibility protein  
BRCA2  Breast cancer type 2 susceptibility protein    
BCT   Breast conservation therapy 
BSA   bovine serum albumin  
oC   degrees Celsius 
DMEM  Dulbecco's Modified Eagle Medium 
DMSO  Dimethyl sulfoxide    
DNA   deoxyribonucleic acid FBS fetal bovine serum 
g   gram 
HPLC   high-performance liquid chromatography 
IFN   interferon 
IL  interleukin 
MTT   Methyl thiazol tetrazolium assay 
NF-kB  nuclear factor kappa-light-chain-enhancer of activated B cells 
nm   nanometer 
PBS   phosphate-buffered saline 
ROS   reactive oxygen species 
 xvii 
 
SDS   sodium dodecyl sulfate 
TNF-α  tumour necrosis factor-α 
TdT   terminal deoxynucleotidyl transferase 
μg   microgram 
μl   microliter 
U/ml   units per ml 
 
 1 
 
Chapter 1. General introduction  
 1.1 Cancer 
Cancer is a deadly disease that is considered one of the most prevalent diseases 
worldwide. Cancer is defined as an abnormal growth of cells in the body due to 
alterations in the expression of several genes, such as the inactivation of tumour 
suppressor genes, the activation of oncogenes, and changes in epigenetic regulation that 
eventually lead to tumour formation (Vogelstein and Kinzler, 2004; Anand et al., 2008). 
The number of cancer deaths in 2007 is estimated at 7.6 million deaths worldwide, and is 
expected to rise to 17 million by 2030 (American Cancer Society, 2007; International 
Agency for Research on Cancer, 2008). In Canada, 206,200 people were diagnosed with 
cancer and 80,800 patients died of cancer in 2017 (Canadian Cancer Society, 2017a). 
Various intrinsic and acquired factors can increase the risk of cancer 
development, such as inherited mutations, stress, alcohol use, unhealthy diet, obesity, 
hormones, infectious diseases, inflammation, harmful chemical use, a lack of physical 
activity, and infection with certain viruses (e.g. papillomaviruses or hepatitis B). In 
addition, cancer can occur following exposure to many forms of DNA-damaging 
radiation, including ultraviolet light and ionizing radiation. Statistics indicate that 5–10% 
of all cancer cases can be caused by genetic disorders, while 90–95% of cancer cases 
occur through lifestyle choices and exposure to environmental agents. Specifically, it is 
estimated that about 25-30% of all cancer-related deaths are caused by tobacco use, while 
30–35% of cancer deaths are associated with an unhealthy diet. It has also been shown 
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that 15–20% of cancer deaths are in response to various infections and the remainder 
occurred through the involvement of a large number of other factors (Anand et al., 2008). 
Cancer is a complex disease that can affect people of all ages (Jemal et al., 2007). 
According to the National Cancer Institute (NCI) classification, cancer can be classified 
into many different types based on the tissue and cell type involved, including 
carcinomas, sarcomas, leukemias, lymphomas, and central nervous system cancers (Jena, 
2012). Carcinomas develop from epithelial cells and make up about 90% of human 
cancers, while sarcomas are considered rare in humans and arise from cells in connective 
tissues, such as muscle, bone, and fibrous tissue. Leukemias and lymphomas constitute 
about 8% of all human malignancies. Leukemias and lymphomas arise from cells of the 
immune system and the blood forming tissues of bone marrow and disseminate through 
the circulation or lymphoid organs, respectively. Lastly, cancers of the central nervous 
system arise from the cells in the brain or spinal cord (Cooper, 2000). 
 Over 100 different types of cancer have been discovered that greatly differ in 
their behavior and in their response to treatment. Some types of cancer are commonly 
diagnosed in men such as liver, colorectal, stomach, lung, and prostate cancer, while 
breast, lung, colorectal, and cervical cancer are the most commonly found types in 
women. Furthermore, cancers can also differ in the number and type of mutations 
present. Mutations in a number of genes that usually regulate the cell division processes, 
which is a balance between stimulators and inhibitors, are frequently involved in cancer 
development. Cancer cells do not respond normally to the signals that regulate cellular 
growth and death because of multiple mutations in these genes and this can eventually 
lead to a loss of regulatory cell growth resulting in the unregulated growth into a tumour 
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(Cooper, 2000, Yankeelov et al., 2011). According to various research findings from the 
Cancer Genome Project, the majority of cancer cells accumulate more than 60 mutations 
(Vogelstein and Kinzler, 2004).  
There are two types of tumours: benign and malignant. Benign tumours do not 
spread or invade other parts of the body. As well, their cells are often more differentiated 
and grow more slowly compared to malignant tumours. Examples of benign tumours are 
uterine fibroids and moles. Benign tumours can cause some damages such as nerve 
damage, tissue death, and a decrease in blood flow because of the compression caused by 
the impact of tumours on tissues or organs; however, benign tumours do not usually 
cause fatal disease. On the other hand, malignant tumours have the ability to invade and 
migrate from the primary site to organs that reside further from the original site via the 
lymphatic system or blood vessels, in a process called metastasis. In addition, malignant 
cells have a higher rate of proliferation, disorganized pattern of growth, avoid 
differentiation, are resistant to apoptosis, and are genetically unstable. Further, malignant 
tumours often contribute to fatal disease (Cooper, 2000). 
The incidence of malignant tumour cases can increase with age, and age is one of 
the most important risk factors of malignancy (Anisimov, 1983). Scientists have several 
hypotheses to explain the direct correlation between age and cancer. Some researchers 
believe that individuals that are exposed to carcinogens for a long period of time may be 
more likely to develop cancer (Peto et al., 1985). Other studies suggest that age can 
provide a suitable environment for malignant cells. For instance, increased proliferative 
senescence can contribute to prevention of apoptosis in malignant cells and enhance 
oncogenic mutations (Anisimov, 1987; Campisi, 2005). The third hypothesis shows that 
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cancer can occur through the interaction of several factors, such as a decrease in the 
effectiveness of the immune system or the accumulation of DNA damage that are 
enhanced, particularly in old age (DePinho, 2000). 
 
1.2 Breast cancer  
Breast cancer is a serious public health problem. Breast cancer is considered the 
most common type of cancer among women worldwide and although it can develop in 
men but at a lower rate. Breast cancer occurs rarely in men, about one in every 100 breast 
cancer cases; however, affected men are less likely to survive the disease than women 
because the majority of breast cancer cases in men are diagnosed at advanced stages 
(Peter and Bernard, 2008; Lakhani et al., 2012).  
A breast consists of three major types of structures: lobules, ducts, and connective 
tissue. Breast cancer can occur in all of the different tissues of the breast but the majority 
of breast cancer cases arise from ducts or lobules. Breast cancer can be associated with 
severe disease or death especially in individuals with acute medical conditions and/or in 
the elderly population. Among women, the second-most frequent cause of cancer-related 
deaths is breast cancer (Russo, 2000). According to the Canadian Cancer Society, 26,300 
women and 230 men were diagnosed with breast cancer in 2017. The number of deaths 
associated with breast cancer is estimated at 5000 women and 60 men in 2017 (Canadian 
Cancer Society, 2017b).  
Breast cancer is diagnosed based on has several morphological characteristics, 
various immunohistochemical profiles, and histopathological subtypes. Multiple distinct 
types of breast cancer have been identified that differ in their ability and to spread to 
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other locations in the body. These types include noninvasive, inflammatory, invasive 
ductal carcinoma, invasive lobular carcinoma, and Paget’s disease of the nipple (Sharma 
et al., 2010). Specifically, invasive ductal carcinoma (IDC), also called infiltrating ductal 
carcinoma, is the most frequent type of breast cancer and constitutes approximately 80% 
of all breast cancer cases. This tumour begins to grow in a milk duct that carries breast 
milk to the nipple and can spread to the surrounding tissues, as well as possibly to other 
places in the body, such as the lymph nodes, bones, and liver (Albrektsen et al., 2010; 
Makki, 2015). 
Invasive lobular carcinoma (ILC) is the second most frequent type of breast 
cancer and constitutes about 10% of all breast cancer cases, although its incidence is 
increasing, particularly among elderly patients. Invasive lobular carcinoma starts from 
epithelial cells in the milk-generating glands (lobules) and over time can metastasize to 
other places of the body (Li et al., 2003). Invasive ductal carcinomas and invasive lobular 
carcinoma are significantly different in terms of clinicopathological features and in their 
response to systemic therapy (Barroso-Sousa and Metzger-Filho, 2016).  
Additionally, in situ ductal and lobular breast cancers are not able to spread to 
other areas of the body, however, if the patients are not appropriately treated these 
tumours can show an increased risk of developing into an invasive breast cancer. Many 
other types of invasive carcinomas have been identified, such medullary and tubular 
breast cancer which make up 5% and 2% of breast cancer cases, respectively, as well as 
less frequent tumours such as adenoid cystic, mucinous, papillary, and low-grade 
adenosquamous carcinoma (Winer et al., 2001; Sharma et al., 2010; Makki, 2015).  
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1.3 Breast cancer risk factors 
Several environmental and hereditary factors can increase the risk of developing 
breast cancer, including being a woman, old age, genetic mutations, hormone therapy, a 
family history of breast cancer, not being active, and excessive consumption of alcohol 
(Mettlin, 1999; Russo, 2000). In addition, there are other factors that are thought to 
increase the risk of developing breast cancer but are still under study, such as smoking, 
sleep patterns, and exposure to environmental toxins (Gram et al., 2016; Lu et al., 2017). 
Evidence shows that inherited genetic mutations can be found in some cases, which are 
present in approximately 5-9% of all breast cancer patients. However, the majority of 
breast cancer cases are linked to somatic mutations that occur in response to various 
environmental factors (Ford and Easton, 1995; Godet and Gilkes, 2017).  
Specifically, age has a significant role in predicting the incidence of breast cancer 
since the majority of breast cancers are diagnosed in women at age 50 - 69 years (Reeder 
and Vogel, 2008). In Canada, statistics indicate that in 2016, about 83% of all breast 
cancer cases appeared in women aged 50 and older. Additionally, having a family history 
of breast cancer can increase the risk of developing the disease. Risk can be higher if one 
or more first-degree relatives, such as parent or sibling, were diagnosed with breast 
cancer. However, the increased risk will be lower if only second-degree relatives, such as 
an aunt or grandmother, were diagnosed with breast cancer (Claus et al., 1990; Colditz et 
al., 1993). 
Inherited mutations in specific genes can increase the risk of developing breast 
cancer at both early and later ages. For example, the BRCA1 and BRCA2 tumour 
suppressor genes that regulate the growth of cells and repair damaged DNA, are the best-
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known genes related to breast cancer and ovarian cancer risk. When mutations that impair 
normal function occur in either of these genes the cells are able to replicate at an 
uncontrollable rate. Researchers have found that the BRCA1 and BRCA2 mutations are 
associated with certain ethnic groups, such as people of Ashkenazi (European) Jewish 
descent. Statistics indicate that about 55 – 65% of females with the harmful BRCA1 
mutation can be affected by breast cancer before age 70. Furthermore, 45% of females 
with the harmful BRCA2 mutation can be affected by breast cancer before age 70 (Couch 
et al., 1996; Greene, 1997). There are other gene mutations that can also lead to 
hereditary breast cancer, such as mutations in ATM, CDH1, CHEK2, PALB2, PTEN, 
STK11, and TP53, but the presence of inherited mutations in these genes are less 
common (De Jong et al., 2002). 
Normally, individuals are exposed to ionizing radiation from natural and medical 
sources, such as radioactive radon gas, radioactive elements (e.g. potassium, uranium, 
and thorium), cosmic rays, medical x-rays, and occupational radiation. However, growing 
evidence shows that exposure to high doses of ionizing radiation or examination by x-ray 
can enhance the risk of developing breast cancer. Furthermore, the carcinogenic effect of 
radiation can be increased as a result of an interaction between radiation and various 
factors, including a woman’s age at exposure, estrogen levels, and genetic profile. 
Women who are exposed to radiation therapy for either malignant or non-malignant 
diseases directed to specific parts of the body, such as the chest, neck, and armpit, show a 
significantly sensitivity to the carcinogenic effects of radiation, especially when the 
patient is treated at a younger age (Preston et al., 2002; Golubicic et al., 2008). For 
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example, the use of radiation therapy to treat Hodgkin lymphoma, particularly in youth, 
can significantly increase the risk of a future breast cancer (van Leeuwen et al., 2003). 
Most epidemiologic studies during the past two decades have indicated that 
consuming alcoholic drinks can increase the risk of developing breast cancer (Singletary 
and Gapstur, 2001). According to the International Agency for Research on Cancer 
(2007), alcoholic beverages are considered a Group 1 carcinogen and can increase the 
risk of breast cancer in women although the mechanisms of increased risk for breast 
cancer by alcohol are not fully understood. Researchers have suggested that alcohol could 
increase the levels of estrogen and androgen which could be a significant mechanism 
underlying the association of alcohol with breast cancer. It has also been suggested that 
alcohol may increase the susceptibility of mammary gland tissue to carcinogens. Studies 
also showed that alcohol could decrease the levels of some essential nutrients that protect 
the cells from damage, including vitamin A and vitamin C (Singletary and Gapstur, 
2001). 
Other factors can be involved, directly or indirectly, in the risk of developing 
breast cancer and many of them are still under study, for example smoking and exposure 
to second-hand smoke (International Agency for Research on Cancer, 2004; Gaudet et 
al., 2013). Although it is not possible to control several risk factors such as being female 
and old age, some environmental factors can be controlled or avoided by changing 
strategic lifestyle, which might lower the risk of breast cancer. Death rates from breast 
cancer have been reduced by 44 % since the peak in 1986 because of increased 
awareness, screening, early detection, and improved treatments. Therefore, early 
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diagnosis of this disease can provide more treatment options and potentially extend the 
patients’ survival for a longer period (Canadian Cancer Statistics, 2015). 
 
1.4 Treatment of breast cancer  
Treatment plans for patients with breast cancer are designed to increase the life 
expectancy of cancer patients or result in a complete cure. The treatment plan for patients 
with breast cancer depends on the subtype of the tumour as determined by screening 
various specific biomarkers such as hormone receptor and HER2 status. Choosing the 
appropriate therapy for patients with breast cancer also depends on different physical and 
biological characteristics of the disease, such as staging, which reflects the tumour size, 
and the extent of cancer spreading. As well, the age of patient, overall health, dosing 
plan, and adverse drug reactions should be considered before the identification of 
treatment. Treatments are divided into local and systemic therapies, including surgery, 
chemotherapy, radiotherapy, and hormonal therapy (McDonald et al., 2016). 
Surgical treatment is the first option that can be used to treat breast cancer. Two 
fundamental types of breast surgery have been identified include breast conserving 
surgery (BCS) and mastectomy. Various factors are taken into consideration before the 
surgical management of breast cancer, such as tumour size, tumour location, the shape of 
the patient’s breast, and patient preference. Breast cancer surgery can also include the 
removal of one or more lymph nodes from the armpit in order to determine if the cancer 
has spread to auxillary lymph nodes. Breast cancer surgery can also include breast 
reconstruction. In advanced cancer, surgery may be performed to relieve symptoms that 
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result when the tumour pressed down on other organs or tissues causing complications or 
pain (McDonald et al., 2016).  
 Breast-conserving surgery (lumpectomy) alone is used to treat stage 0 ductal 
carcinoma in situ whose area is estimated at < 0.5 cm in diameter. In this surgery, tumour 
tissues and nearby margins that might be cancerous are removed. Larger tumours require 
adjuvant radiation therapy in addition to a lumpectomy. On the other hand, mastectomy, 
to remove the entire breast including all of the breast tissue and nearby tissues, in 
combination with adjuvant tamoxifen therapy is commonly employed in order to treat 
extensive ductal carcinoma in situ (Fisher et al., 1998). Furthermore, auxiliary lymph 
node status should be considered in patients with stage I or II breast cancer followed by 
lumpectomy and radiation therapy (Arriagada et al., 1996). 
Radiation therapy (also known radiotherapy) is one of the more common 
treatment modalities prescribed for breast cancer patients. External beam radiation is the 
most common form of radiotherapy used for patients with breast cancer. External 
radiation uses a machine to direct a beam of X-rays to destroy the patient's tumor and can 
be applied in different ways such as hypofractionated radiation therapy, 3D-conformal 
radiotherapy, and intraoperative radiation therapy (Mondal and Sharma, 2016). Radiation 
therapy can be used at various times during the course of breast cancer treatment, 
including following surgery to reduce the risk of local and regional recurrences, before 
surgery to reduce the tumour size, or to mitigate pain or symptoms of advanced disease. 
Some patients with stage 0 ductal carcinoma in situ and the majority of patients with 
stage 1 or higher invasive cancers receive radiation therapy as a part of their treatment 
plan (Poortmans, 2007; McDonald et al., 2016). Studies showed that including 
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radiotherapy for treatment of breast cancer was able to lengthen survival time and 
decrease the mortality rate (Vinh-Hung and Verschraegen, 2004). 
Chemotherapy is used as a treatment option for various types of breast cancer and 
can be administered intravenously, given orally, and sometimes injected into the spinal 
fluid. The majority of chemotherapy is used as a systemic therapy, which means drugs 
flow throughout the body to kill the cancer cells or inhibits their growth and division. It 
can be used as a primary treatment (neoadjuvant) before surgery or radiation treatment, 
especially for individuals that have locally advanced breast cancer. Neoadjuvant 
chemotherapy can shrink the size of a large tumour prior to surgery and can also be used 
with some types of breast cancer, such as inflammatory breast cancer (Bonev et al., 
2014). Adjuvant therapy, this which is used after surgery but before radiation therapy, is 
often used in order to prevent recurrence of the disease (Anampa et al., 2015).  
Chemotherapy can be used as the first therapy or in combination with other 
therapies for the treatment of metastatic breast cancer cases or to relieve symptoms. 
Using a combination of chemotherapy drugs is more effective than using just a single 
agent and treatments usually involve combinations of two or three drugs (Carrick et al., 
2009). The common types of chemotherapy drugs are classified as anthracyclines, 
taxanes, carboplatin, and cyclophosphamide. Other treatment approaches can include 
hormonal treatment and targeted therapies, which have been used for some types of 
breast cancer (Pegram et al., 2004). 
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1.5 Side effects of some treatments 
The various methods used to treat cancer can also have adverse side effects and 
remarkable toxicities associated with breast cancer therapies have been identified. The 
side effects resulting from external radiation therapy, include swelling in the breast, skin 
peeling, secondary malignancy, fatigue, difficulty in breastfeeding later on for some 
women, lymphedema, and cardiac and pulmonary toxicity (Brown et al., 2015). While 
the majority of these side effects are temporary, there may be permanent or long-term 
effects in some cases including permanent changes in cardiac and pulmonary function. 
For example, many studies have shown an increase in the death rate by cardiac disease 
for individuals who received radiation for left-sided breast cancer (Clarke et al., 2005; 
Darby et al., 2005). Other studies have reported that nerves in the arm could be damaged 
by radiation, which can lead to pain, shoulder weakness, and numbness (McCredie et al., 
2001). 
Chemotherapy drugs can also cause several side effects, which can adversely 
impact the quality of life for individuals in the short and long term. These adverse effects 
include vomiting, weight changes, hair loss, neuropathy, hormonal shifts and early 
menopause, loss of fertility, mouth sores, diarrhea, etc. In breast cancer survivors, fatigue 
is observed to a greater extent in patients who had received chemotherapy compared to 
patients who were treated with other options (Goedendorp et al., 2012).  
Furthermore, researchers have shown that chemotherapy treatments can accelerate 
menopause in young females, leading to loss of fertility and various physiological 
symptoms, such as hot flashes and night sweats (Rosenberg and Partridge, 2013). Studies 
show that chemotherapy can increase the risk of opportunistic microbial infections by 
 13 
 
affecting the immune system. It can also affect the self-renewal of epithelial cells, which 
can disrupt barriers that protect the host from invasion by microorganisms (Khan and 
Wingard, 2001; Elting et al., 2003).  
 
1.6 Importance of medicinal plants 
Since ancient times humans have widely used natural products for the treatment 
and prevention of disease. The natural products used today were often identified from 
traditional use due to their pharmacological properties and the belief that herbal therapies 
have a relative lack of toxicity. Natural products traditionally were the basis of the 
majority of early medicines; several communities, such as Native American, European, 
Egyptian, Indian, Greek, and Chinese communities, have all used herbs as a primary 
source of healthcare. For example, herbs have been used to decrease stress, support the 
immune system, increase relaxation, and improve disease symptoms. These herbs were 
given orally to individuals or pasted on the diseased area to mitigate pain, injuries, and 
maintain wellness (Pal and Shukla, 2003; Hong-Fang et al., 2009).  
Natural products fell out of use in western medicine following the industrial 
revolution and the discovery of modern drugs, but recently, there has been a renewed 
interest in the use of natural products (Pal and Shukla, 2003; Koehn and Carter, 2005). 
Evidence shows that many developed countries, such as Canada, United Kingdom, 
Europe countries, and Australia, have recently increased the use of complementary and 
alternative medicine (CAM) to serve as potentially safe and effective therapeutic agents 
(Calapai, 2008; Braun et al., 2010; Anquez-Traxler, 2011). In some parts of the world, 
such as China, India, and South America, natural products have always been used for 
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treatment of disease. Statistics indicate that about four billion people worldwide rely on 
medicinal herbs to maintain health and promote safety. For example the proportion of 
people who were consumers of CAM in the United States increased from 34% to 42% 
during the period of 1990-1997 (Eisenberg et al., 1993; Eisenberg et al., 1998).  
Studies have demonstrated that a large number of medicinal herbs contain 
antioxidant, anticancer, anti-inflammatory, immunomodulatory, and anti-microbial 
activity. Multiple plant extracts have been tested in vitro and in vivo against various kinds 
of diseases, including many types of cancer (e.g. lung cancer, skin cancer, prostate 
cancer, breast cancer, etc.), Alzheimer’s disease, lung dysfunction, respiratory infections, 
and cardiovascular diseases using modern techniques. It should be noted that the efficacy 
of these medicinal herbs, their biological properties, composition, and their potential to 
treat various diseases have been analyzed in many studies (Koehn and Carter, 2005; 
Saklani and Kutty, 2008; Aravindaram and Yang, 2010). 
Several pharmacological and chemical studies have shown that extracts from the 
stems, roots, bark, leaves, fruits, and seeds of some plants have the ability to provide very 
specific biological activities. The extracts have been shown to contain a large diversity of 
chemicals with unique molecular structures and a greater complexity than can be present 
in small molecule synthetic drugs (Gonzales and Valerio, 2006). In addition, some herbal 
medicines can contain a number of natural components that can affect many disorders at 
the same time by targeting several different mechanisms. Various studies have shown that 
more than 119 different chemical components have been obtained from extracts of 
various types of plants and developed into new drugs (Farnsworth et al., 1985).  
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Ecological conditions and cultivation technologies can affect the ability of the 
plant to produce different chemical components, which determines the effectiveness of 
the extract against disease. These include differences in the type of ground (e.g. climate, 
soil quality, etc.), time of harvest, manufacturing process, length of storage, and 
geographical location. One of the important examples is the soil the plant is grown in. 
Soil contains several nutritional elements (e.g. potassium, nitrates, phosphorous, etc.), 
which play a primary role in plant growth, the creation the structures of plant tissues, and 
the metabolic activity of the plant. Consequently, the medicinal quality of the plant 
extracts represents and reflects the environment that the plant is grown in (Barlóg, 2002; 
Liu et al., 2007). 
Recent studies exploring the applications of traditional medicine has shown that 
patients have become more accepting of treatments based on CAM (Frass et al., 2012). 
The reasons for this acceptance include the high cost of conventional medicine, especially 
in some developed countries, as well as the acute side effects resulting from the use of 
some synthetic drugs (Fraenkel et al., 2004; Pagan and Pauly 2005). In the sphere of anti-
cancer therapy, researchers showed that CAM can play a significant positive role in 
enhancing the quality of life of some cancer patients in terms of the physical, emotional, 
psychosocial, and social effects. Although there is no evidence to indicate that CAM can 
replace conventional treatment, an increasing number of cancer patients will eschew 
conventional chemotherapy / radiation treatment in favor of “alternative medicine”. 
Having the ability to bridge “alternative medicine” and conventional modern cancer 
therapies allows for an expanded range of treatments that may help divert reluctant cancer 
patients into evidence-based treatment programs (Adams and Jewell, 2007). 
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Statistics indicate that 60% of drugs approved by the food and drug administration 
(FDA) during the period of 1984 to 1994 were originally obtained from plants (Kumar et 
al., 2012). Furthermore, of the 121 anticancer drugs that have been approved it was 
shown that 90 anticancer drugs were derived from medicinal herbs. Some examples of 
anticancer drugs derived from natural source origins include; topotecan, etoposide, 
podophyllotoxin, paclitaxel, vincristine, and camptothecin (Mukherjee et al., 2002; Cragg 
et al., 1997). Extensive research ﬁndings have shown that natural products can play a 
huge role in the development of new drugs. Further, the use of natural products may 
become more popular as the therapeutic active ingredients are identified and their 
efficacy demonstrated to be as good as some conventional treatments, as well as being 
more cost-effective (Rajesh et al., 2015). 
 
1.7 Side effects of some herbs 
Although an enormous number of plants may have medical value and promising 
potential, a large proportion of plants have still not been tested for clinical value; they 
have either been poorly monitored or have not yet been tested at all. Unfortunately, a 
large number of plant extracts that are currently promoted for use by patients have also 
not been properly investigated. These untested plants need to proceed to animal-based 
preclinical experiments and then to human clinical trials before it is possible to assess the 
complete range of side effects and other potential complications from treatment with 
these extracts. It should be noted that a number of plants contain components that have 
high toxicities and can cause serious adverse effects, such as hepatotoxicity, 
cardiotoxicity, and nephrotoxicity (Ekor, 2013). For instance, plants used in Traditional 
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Chinese Medicine that contain aristolochic acid can cause kidney failure and are 
considered a strong carcinogen (Yang et al., 2014).  
Studies show that some herbs have high toxicities due to the presence of non-
organic pollutants in their products such as lead, mercury, and arsenic. In addition, 
allergic reactions can be caused by several components isolated from plants, such as 
salicylic glycosides and lactonic sesquiterpenes (Bent and Ko, 2004; Firenzuoli and Gori, 
2007). Therefore, plants must be adequately tested before they should be recommended 
as new strategies to improve anticancer response rates and response to side effects, and to 
potentially extend patients’ survival. As well, relevant regulatory authorities should be 
involved to inform and sensitize the general public about the rational and safe use of 
herbal medicines (Ekor, 2013). 
 
1.8 Apoptosis 
One of the major tests to determine the potential anti-cancer potential of treatment 
with a natural product or other therapeutic is its ability to induce apoptosis in treated 
cells. Apoptosis, or programmed cell death, is a physiological process that has a 
significant role in the development and homeostasis in normal tissues. It normally acts as 
a defense mechanism by removing the damaged and injured cells caused by various 
diseases, such as ischemic damage and cancer. Apoptosis also plays a major role in a 
number of processes such as normal cell turnover, embryonic development, and the 
immune system response. Several morphological features have been identified for 
programmed cell death, including reduction in cellular volume, chromatin condensation, 
DNA fragmentation, and membrane blebbing. Ultimately, cell components are packaged 
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into apoptosomes that are degraded via macrophages. Together, apoptosis is considered a 
type of cell death that has a programmed sequence of events leading to cell degradation 
without causing harmful effects in the surrounding area (Elmore, 2007). 
Additionally, there are a large number of stimuli that lead to apoptosis and cells 
can die differently depending on the cell type involved as well as physiological and 
pathological conditions. Although several apoptotic proteins have been identified, 
researchers are still learning more about the molecular mechanisms of action of these 
proteins in order to provide a better understanding of how apoptosis is activated. Two 
pathways, called the extrinsic or, “death receptor,” pathway and the intrinsic or 
“mitochondrial” pathway regulate apoptosis. In the extrinsic pathway, extracellular 
ligands bind to death receptors in the plasma membrane due to the activation of specific 
signals generated from other cells. For example, specific Tumor necrosis factor-like 
cytokines, such as TRAIL or Fas Ligand, released by neighboring cells, bind to and 
activate specific TNF receptor-like death receptors, such as TNF-R1 and Fas, activating 
downstream apoptosis activators. This process results in the activation of proteases called 
caspases (in particular caspases 6 and 8) that cleave a variety of important target proteins 
leading to apoptosis (Wong, 2011).  
Under cell stress, the intrinsic pathway is activated via intracellular signals to 
increase the permeability of the mitochondria. Several internal stimuli can initiate this 
pathway, including hypoxia and severe oxidative stress (Karp, 2008). The process is 
summarized in the release of cytochrome c from the mitochondria into the cytoplasm, 
leading to the activation of caspases (including caspase 9 and 3), which then degrades 
important molecules in the cell (Danial and Korsmeyer, 2004). Many factors have been 
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identified to promote apoptosis (pro-apoptotic proteins), such as Bax, Bak, Bid, Bcl-Xs, 
and Bok/Mtd, which form permeability pores in the mitochondrial membrane to enhance 
the release of cytochrome c while other members of the Bcl family inhibit apoptosis 
(anti-apoptotic proteins) by preventing formation of permeability pores, such as Bcl-2, 
Bcl-xL, Mcl-1, XIAP and Bcl-B/Bcl2L10 (Reed, 1997; Elmore, 2007). The process of 
apoptosis from the initiation of cell death to the final cellular fragmentation normally 
takes several hours to days and the duration relies on many factors, such as the stimulus 
and the type of cell (Ziegler and Groscurth, 2004). 
Apoptosis has been implicated in the pathological conditions underlying serious 
diseases such as cancer, degenerative diseases, autoimmunity, and atrophy, which may 
result from excessive or insufficient apoptosis. In terms of cancer, the mechanism of 
programmed cell death is complicated and is highly regulated at many levels. The 
existence of defects in any of these levels may lead to a loss of balance between cell 
division and cell death, eventually causing cancer. Furthermore, decreased caspase 
function and impaired death receptor signaling can occur because of the reduction in 
apoptosis (Wong, 2011). Studies show that defective apoptosis contributes to and 
enhances tumor progression. One of the examples in promoting carcinogenesis is an 
alteration in the expression of members of the Bcl-2 family, which regulate the intrinsic 
apoptotic pathway. For example, increased levels of Bcl-2 play a significant role in 
blocking apoptosis and promoting cell survival (Vaux et al., 1988) and can promote it to 
act as an oncogene as in human leukemia and follicular lymphoma (Tsujimoto et al., 
1984; Tsujimoto et al., 1985). 
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 The downregulation of p53 can also promote carcinogenesis; p53 is a tumor 
suppressor encoded by the tumour suppressor gene TP53 that has a strong link to 
apoptosis. Mutations in p53 are found in most human tumours (about 50%) and are linked 
to advanced tumour stage (Wallace-Brodeur and Lowe, 1999; Bai and Zhu, 2006). p53 
also has a critical role in development, differentiation, gene amplification, cell cycle 
regulation, and DNA recombination (Lane, 1992). Yonish-Rouach et al. (1991) indicated 
that p53 can enhance apoptosis; however, in a myeloid leukemia cell line overexpression 
of p53 was able to promote cell survival and reduce apoptosis. Together, apoptosis can 
play a significant role in both normal physiological development and in pathological 
conditions. 
Several components extracted from different plants have been used as inducers of 
apoptosis in cancer treatment. One example of a plant extract that can promote apoptosis 
is curcumin. Curcumin is a phenol component of the spice tumeric and is promoted as an 
effective treatment for several types of cancer such as gastric, prostate, colorectal, and 
pancreatic cancer (Taraphdar et al., 2001; Qi et al., 2010). Curcumin can suppress the 
NF-Kβ signaling pathway in order to increase the response of tumor cells to doxorubicin. 
It also has the ability to promote other anticancer factors to enhance the success of 
treatment of multi-drug resistance (Hemaiswarya and Doble, 2006). It should be noted 
that curcumin did not show toxicity in human patients treated in clinical trials at a dose of 
8000 mg/day (Ramachandran et al., 2005). Another example of a plant extract that can 
promote apoptosis is genistein, which is a phytosterol from the flavonoids family of 
compounds. Genistein can significantly stimulate apoptosis in human pro-myelocytic 
HL-60 leukaemic cells (Qi et al., 2010). Genistein can also block proliferating cells 
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during the cell cycle in the G2/M phase, inhibit tyrosine kinases, and block angiogenesis 
(Wheat and Currie, 2008). 
 
1.9 Immune system 
The immune response can be categorized as two types of immune responses: 
innate immunity and adaptive immunity. Innate immunity refers to a nonspecific defense 
mechanism that acts very quickly against invading foreign bodies, such as bacteria or 
viruses, to mediate a primary response in inflammation. The innate immune system 
includes physical barriers to infection as well as a system of signaling receptors for 
structural components of bacteria and/or viruses that activate changes in gene expression 
and protein secretion in response to an infection. These receptor systems are highly 
expressed on neutrophils, monocyte/macrophages, and dendritic cells, which can both 
physically destroy pathogens via production of free radicals and phagocytosis and 
activate other components of an immune response by the production and secretion of 
cytokines and chemokines. However, the innate immune system does not change in 
response to infection and does not show a “memory” based on reinfection with the same 
pathogen. In contrast, adaptive immunity shows changes in responsiveness to an 
infectious agent such that the responses are accelerated and more intense following 
reinfection with the same pathogen. Adaptive immune responses involve stimulation of 
clones of T and/or B lymphoctes in an antigen-specific manner which can destroy 
infected cells, produce antibodies against the foreign antigen, or release cytokines and 
chemokines to recruit macrophages to destroy the foreign antigen. Further, the adaptive 
immune system can develop very specific responses to a specific antigen on the target 
and can “remember” those specific antigens for extended durations even in the absence of 
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reinfection. Immune cells such as macrophages, dendritic cells, natural killer (NK) cells, 
NK T cells, and γδ T cells can act as a bridge between innate and adaptive immunity 
(Chien et al., 1996; Murphy et al., 2008; Waldhauer and Steinle, 2008; Sun and Lanier, 
2009). 
Natural killer cells and phagocytes, such as neutrophils, monocytes, and 
macrophages, have a major role in cell-mediated innate immune responses. NK cells are a 
subpopulation of lymphocytes of the innate immune system, which have been shown to 
control many types of tumours and cells with viral and microbial infections. NK cells 
have the ability to recognize abnormal cells that express low levels of “self-antigens” in 
response to multiple pathological challenges and can respond quickly to kill the abnormal 
cell by releasing perforin and granzyme to induce apoptosis. In this way, cells infected 
with viruses or bacteria are killed before they are able to produce new infective agents. 
On the other hand, phagocytes can also kill a wide range of tumour cells and 
microorganisms by production of free radicals and by phagocytosis. Phagocytes can also 
ingest and engulf dead cells and debris that result from tissue injury. The process of 
phagocytosis involves enveloping the pathogen within a vesicle formed by involution of 
the cell membrane, called the phagosome, which then fuses with lysosomes to destroy 
microorganisms (Sun and Lanier, 2009). Additionally, several cells such as eosinophils, 
basophils, and mast cells can secrete inflammatory mediators, such as proteolytic 
enzymes, vasoconstrictors, and cytokines, to participate in cellular innate immunity 
(Murphy et al., 2008).  
Cells of the adaptive immune system are extremely specialized defender cells, 
called lymphocytes, including B cells and T cells. Both B cells and T cells arise from 
 23 
 
multipotent hematopoietic stem cells in the bone marrow (Murphy et al., 2008). T cells 
then mature in the thymus to generate αβ T cells and γδ T cells, which are two kinds of T 
cells characterized by distinct T-cell receptors (TCR) expressed on their surface. 
Specifically, a small group of T cells are classified as γδ T cells, while the majority of T 
cells are αβ T cells, which can be further divided into two subsets known as CD4+ T 
helper cells and CD8+ cytotoxic T cells (Chien et al., 1996; Koretzky, 2010; Luckheeram 
et al., 2012).  
T cells are selected in the thymus for the ability to respond to a specific antigen 
before being released into circulation. The initial activation of T cells occurs in peripheral 
lymphoid organs, when the T cell receptor (TCR) on either a CD4+ helper T cell or a 
CD8+ cytotoxic T cell binds to a peptide derived from the specific “foreign” antigen held 
within in the major histocompatibility complex (MHC) expressed on the surface of the 
antigen- presenting cell (APC), such as a dendritic cell or macrophage. The interaction 
between the T cell receptor and the peptide-MHC complex must be accompanied by a 
secondary signal for activation of helper T cells and cytotoxic T cells. Secondary signals 
include interactions of the co-receptor protein CD28 on the surface of the T cell with the 
B7 proteins (CD80 and CD86) expressed on the surface of the APC, which leads to T-cell 
proliferation (Smith-Garvin et al., 2009).  
There are three common classes of effector T cells in circulation, including T 
helper cells, regulatory T cells (Treg), and cytotoxic T cells. Two types of helper T cells 
have been identified; TH1 and TH2 cells. TH1 cells secrete IFN-γ and interleukin-2 (IL-
2) that are essential for cell-mediated immunity. TH2 cells secrete interleukin-4, (IL-4) 
IL-5, IL-10, IL-13, and IL-31 in order to regulate the immune responses to extracellular 
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pathogens. Moreover, TH1 cells activate macrophages, B cells, and cytotoxic T cells, 
while TH2 cells stimulate the differentiation of B cells into antibody-secreting plasma 
cells (Gutcher and Becher, 2007). Treg play an important role in regulating different 
aspects of immune reactions. They can secrete transforming growth factor-beta (TGF-β), 
IL-35, and IL-10 to decrease inflammation (Workman et al., 2009). Cytotoxic T cells are 
activated through many cytokines to directly destroy the targeted invaders via release of 
perforin and granzyme (Andersen et al., 2006).  
B cells are a primary component of the humoral immune response of the adaptive 
immune system. B cells differentiate into plasma cells that are responsible for generating 
antibodies, and can produce immunological memory, antigen presentation, and regulatory 
cytokine production. B cells are activated in the secondary lymphoid organs, such as the 
spleen and lymph nodes. Activation of B cells occurs through antigen recognition by the 
B-cell receptors (BCRs) and signals produced by helper T cell receptors such as CD40 
and by T cell cytokines. This activation leads to proliferation of the B cells and their 
differentiation into either memory cells or antibody-secreting effector cells (Hoffman et 
al., 2016). 
 
1.10 Immune system responses in cancer 
Recently, a wide range of studies has focused on the role of the immune system in 
cancer. Evidence indicates that the interactions between tumour cells and different 
components of the immune system are very complicated and can continuously change. 
This means immune responses can potentially play a significant role in anti-tumour 
immunity or conversely can enhance tumour growth. Further, the interaction between 
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tumours and the immune system can alter the tumour cells in a process called 
immunoediting. Three phases in the cancer immunoediting process have been 
determined, including elimination, equilibrium, and escape. In the elimination phase, the 
innate and adaptive immune systems are able to protect the host by recognizing and 
inhibiting tumour cell proliferation and survival (Kim et al., 2007). 
 If the tumour cells are not fully rejected during the elimination phase, they enter 
the equilibrium phase. The equilibrium is the longest period in the immunoediting 
process and is characterized as a balance between the progression of cancer and cancer 
elimination by the immune system. During this phase, the immune system is still active 
against the tumour and can control tumor growth and metastasis but does not fully 
eliminate the tumour. Over time however, the cancer may proceed to the escape phase by 
developing many mechanisms to avoid immune surveillance and stimulate tumour 
tolerance (Kim et al., 2007). Mechanisms activated during the escape phase include 
downregulation of expression of classical MHC class I expression, increased expression 
of PD-L1, upregulation of suppressive T cells, and orchestration of an 
immunosuppressive microenvironment. Researchers have speculated that the appearance 
of clinical symptoms of cancer are linked to the escape phase (Dunn et al., 2004, 2006; 
Schreiber et al., 2011; Mellman et al., 2011; Chen and Mellman, 2013).  
Generally, during the development of cancer many components of the innate and 
acquired immune systems are activated in order to prevent tumour growth and 
progression. In terms of the innate immune response, inflammatory cytokines can be 
released by, or in response to, the growing tumour cells and stromal cells in the 
surrounding area. These inflammatory cytokines can activate various innate immune 
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cells, such as NK, NK-T, γδ T cells, macrophages, and DCs in the area of the tumour. In 
particular, NK cells are the most significant components of the innate immune system 
that combats the cancer cells in the early stages of carcinogenesis (Dunn et al., 2002). NK 
cells have the ability to detect some transformed cells, since tumour cells frequently 
downregulate MHC class I antigen, which leads to the destruction of these transformed 
cells and removal of their fragments via macrophages and dendritic cells. NK cells use 
various mechanisms to inhibit their targets such as secretion of IFN-γ for activation and 
maturation of antigen presenting cells, or by production of TNF-α, as well as by induction 
of apoptosis, which relies on the secretion of perforin, and granzyme to introduce pores 
into the cancer cell membranes. NK cells can also express Fc receptors for IgG (CD16) 
on their cell surface which can kill infected cells that are coated with IgG by a process 
called antibody-dependent cell-mediated cytotoxicity (Waldhauer and Steinle, 2008). 
NK-T cells can also play a significant role in regulating immune responses to 
tumour cells. NK-T cells can release IFN-γ in order to activate the effector functions of 
both NK cells and CD8+ T cells which in turn can induce apoptosis in the tumour cells. 
For example, an interaction between NK-T cells and dendritic cells through CD40 ligand-
CD40 signaling leads to the release of IL-12, which is then able to activate the NK or 
CD8+ T, cells to inhibit cancer progression (Terabe and Berzofsky, 2008). Other cells, 
such as γδ T cells, can stimulate cell death in malignant cells. γδ T cells can also 
recognize tumour antigens via CD16 (Fc receptor) in order to mediate antibody-
dependent complement cytotoxicity (Gogoi and Chiplunkar, 2013).  
Proteins produced due to mutations in the tumour cells can be recognized by the 
adaptive immune system. Research has shown that both T cells and B cells can recognize 
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tumor-specific antigens that are expressed following specific mutations. For example, 
CD4+ T cells in melanoma have been shown to recognize a tumor-specific antigen 
containing a non-synonymous point mutation, which is located in the gene coding for 
triosephosphate isomerase (Wang et al., 1999). Also in melanoma, CD4+ T cells can 
recognize a tumor-specific antigen formed by a chromosomal rearrangement that leads to 
the fusion of a low-density lipid receptor gene with a fucosyltransferase gene (Wang et 
al., 1999). In another study, CD8+ T cells were shown to recognize p16INK4a with a 
point mutation in a melanoma patient (Wolfel et al., 1995). Moreover, many CD8+ T cell 
epitopes were generated by the presence point mutations in proteins from patients with 
non-small cell lung cancer (Echchakir et al., 2001; Karanikas et al., 2001). 
The expression of cell surface markers on the surface of the cancer cells can be 
changed in response to genetic and epigenetic alterations (Pinho and Reis, 2015). For 
example, the expression of the MHC class I protein on the surface of the cells is 
considered a marker of all nucleated cells. In the cancer cells, reduction in the expression 
of the MHC class I protein is observed. This reduction can allow the NK cells to induce 
apoptosis in the cancer cells in response to binding NKG2D receptors located on the NK 
cell surface, to MICA/B located on the tumour cells. Normal expression of MHC class I 
can inhibit NK cells by activating inhibitory receptors, which eventually leads to 
apoptosis resistance (Waldhauer and Steinle, 2008).  
Additionally, mutation in genes associated MHC class I antigen presentation have 
been identified. Studies showed that mutations in these genes can lead to a loss of 
function in CD8+ T cells, which can recognize cancer cells (Garrido et al., 1997). In 
particular, mutations in the β2-microglobulin gene, which has a primary role in MHC 
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class I molecule expression on the cell surface, have been reported (D’Urso et al., 1991; 
Perez et al., 1999). Due to the downregulation of surface MHC class I molecules and 
appearance of immunosuppressive factors, cancer cells can become resistant to CD8+ T 
cells and NK T cells and can escape from immune recognition (Garrido et al., 1997).  
Another mechanism cancer cells use to evade the immune response is to release 
an abnormally high amount of transforming growth factor β (TGF-β) and IL-10, which 
are classified as immunosuppressive cytokines that can enhance cancer progression. 
TGF-β is both a tumor suppressor and a tumor promoter. TGF-β can be a strong inducer 
of apoptosis in early stages of cancer. In other cases, TGF-β signaling works in a contrary 
manner and enhances tumor growth (Principe et al., 2014; Lippitz, 2013).  
Innate immunity can play a significant role in the development of cancer by 
increasing secretion of proteases such as neutrophil elastase, which exists in neutrophil 
granules, and supporting the growth of cancer cells. Other proteases can cleave 
extracellular matrix proteins, which can enhance metastasis. Moreover, neutrophils 
express NADPH oxidase that generates reactive oxygen species (ROS). ROS has the 
ability to stimulate cancer invasion through genetic modifications (Gregory and 
Houghton, 2011). Cancer cells can produce thymic stromal lymphopoietin, which can 
upregulate OX40 ligand expression on dendritic cells, and other APCs (Palucka and 
Banchereau, 2012). Expression of OX40 on T cells can interact with the OX40 ligand on 
APCs to work as a secondary co-stimulatory signal to CD28 signaling which can activate 
T cells and differentiate them into the TH2 T cell subset (Sharpe, 2009).  
Many regulatory factors have been identified that function as immune checkpoints 
in the adaptive immune responses. Research has shown that tumour cells can hijack the 
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immune checkpoints in order to promote the inhibition of immune surveillance. In the 
first interaction between antigen/MHC class II receptors on APCs and T cell receptors, a 
second co-stimulatory signal is also required, such as CD28 and ICOS (Sharpe, 2009). 
An interaction between the ICOS ligand on APCs and the ICOS receptor on T cells 
occurs, while an interaction between CD28 on T cells and CD80 (B7.1)/CD86 (B7.2) on 
APCs can promote activation of the naïve T cells (Podojil and Miller, 2009; Sharpe, 
2009). Dysregulation of costimulatory signals can disable the function of the T cell and 
block activation of adaptive immunity, promoting the progression of cancer (Crespo et 
al., 2013). 
T cells can upregulate two co-inhibitory molecules; cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) and programed death 1 (PD-1) on the cell surface. 
Normally, these co-inhibitory molecules control the excess of T cell activation. In the 
case of cancer, increased expression of CTLA4 has been observed in various types of 
cancer cells. As well, expression of PD-L1 has been found in several types of cancer, 
which significantly contribute to the escape phase. In addition, researchers have shown 
that an interaction between CTLA4 on T cells and the CD80/CD86 proteins on APCs 
enhances immune tolerance. Taken together, the innate and adaptive immune responses 
can participate in preventing tumour growth and cancer progression (Podojil and Miller, 
2009; Sharpe, 2009). 
 
1.11 Uncaria tomentosa 
Uncaria tomentosa is distributed in various places, including the Amazon 
rainforest and throughout South and Central America. Commonly known as Cat’s Claw, 
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U. tomentosa is a large woody vine in the Rubiaceae family and Cinchonoideae 
subfamily. This species is found in the Tropical rainforest, which grows up to 30 metres 
in height and has leaves that contain a smooth edge that grows in two opposite whorls. U. 
tomentosa has been historically used in Peru as a traditional medicine to treat several 
disorders. Currently, U. tomentosa is provided commercially as a dietary supplement and 
is considered one of the best-selling herbs in industrialized countries such as the United 
States and in Europe (Keplinger et al., 1999; Zhang et al., 2015). 
In many places in the world such as Peru, Germany, Austria, England, Japan, 
Canada, and the United States, multiple studies have been conducted on U. tomentosa 
extracts (Honório et al., 2016). These studies showed that the plant has activity in the 
treatment of a number of diseases, such as cancer, AIDS, gastrointestinal disorders, 
diabetes, respiratory infections, rheumatoid arthritis, herpes, epidemic diseases, and 
multiple sclerosis (Zhang et al., 2015). Analytical characterization of the plant extracts 
showed that cat’s claw contains various active components, such as alkaloids, quinovic 
acid glycosides, polyhydroxylated triterpenes, catechins, sterols, and flavonoids that can 
have significant antioxidant, anti-inflammatory, and anti-neoplastic properties (Laus et 
al., 1997; Heitzman et al., 2005; Luna-Palencia et al., 2013).  
Since 1985, many studies have been conducted on the alkaloids obtained from U. 
tomentosa to test the effectiveness of this plant and identify its active components. Most 
these studies showed that pentacyclic oxindole alkaloids are a rich resource for drug 
discovery and can be responsible for many of the biological activities in this plant 
(Wagner et al., 1985; Reinhard, 1999; Bacher et al., 2006; Paniagua-Pérez et al., 2009). 
However, some other studies showed that different components such as triterpenes and 
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quinovic acid glycosides might play a significant role in the useful outcomes that are 
produced by U. tomentosa (Aquino et al., 1990, 1991). In addition, a group of scientists 
believed that these various components work together synergistically to produce 
pharmacological effects (Rizzi et al., 1993; Reinhard, 1999). 
Researchers have assessed the efficacy of many compounds derived from U. 
tomentosa extracts against several cancer cells in vitro and in vivo. They found that cat’s 
claw had effective actions in cancer therapy by suppressing the growth of these cancer 
cells, including human neuroblastoma, glioma, MCF-7 breast cancer, and HL60 
promyelocytic leukaemia cells (Sheng et al., 1998; Riva et al., 2001; Pilarski et al., 
2007).  
Kośmider et al. (2017) examined the cytotoxic effects of the tetracyclic alkaloid-
free aqueous extract of U. tomentosa against both normal (NHDF) and cancer (HepG2) 
cells. The U. tomentosa extracts showed cytotoxic effects against HepG2 cells. However, 
the plant was not cytotoxic to the NHDF cells. In HepG2 cells, U. tomentosa extracts 
increased ROS production and reduced GSH levels. It caused apoptosis in the HepG2 
cells by activation of caspase-3 and caspase-7. The plant extract also decreased the 
activity of NF-κB in cancer cells. In contrast, ROS production, GSH level, and NF-κB 
activity were not affected in the non-malignant cells (Kośmider et al., 2017). 
A study by Rinner et al. (2009) used fractions derived from U. tomentosa to treat 
MTC cells. They found that U. tomentosa extracts inhibited the growth of MTC cells and 
the enzymatic activity of mitochondrial dehydrogenase. In addition, the expression of 
caspase-3 and -7 and poly (ADP-ribose) polymerase (PARP) fraction was increased. 
However, bcl-2 expression was not changed. Specifically, MTC cells that were treated 
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with the alkaloids isopterpodine and pteropodine isolated from U. tomentosa showed 
remarkable pro-apoptotic properties; while treatment with the alkaloid-poor fraction 
reduced cell proliferation but did not induce pro-apoptotic effects (Rinner et al., 2009). 
Different types of oxindole alkaloids, including isopteropodine, pteropodine, 
isomitraphylline, uncarine F, and mitraphylline were extracted from U. tomentosa and 
then tested against human lymphoblastic leukaemia T cells (CCRF-CEM-C7H2). Four of 
them prevented the proliferation of lymphoblastic leukaemia cells. Furthermore, 
pteropodine and uncarine F showed significant pro-apoptotic effects on leukaemic 
lymphoblasts (Bacher et al, 2006). 
Due to its ability to promote DNA repair and reduce harmful side effects, pain, 
and mutations caused by chemotherapy, U. tomentosa has been used as an adjunct 
treatment for breast cancer patients undergoing treatment (Araújo et al., 2012). Clinical 
trial data supports the ability of treatment with extracts of this plant to mitigate weight 
loss, nausea, secondary infections, and hair loss in patients treated with chemotherapy. 
Moreover, studies have demonstrated that U. tomentosa increases the number of myeloid 
progenitors (Sheng et al., 2000; Riva et al., 2001; Araújo et al., 2012). The immune 
system response, such as the proliferation of normal T and B lymphocytes, are also 
regulated in response to U. tomentosa (Wurm et al., 1998). Cytokines, such as IL-1, IL-6, 
and TNF-α, are also regulated via treatment with extracts of this plant (Allen-Hall et al., 
2007). 
Continuing research has found that U. tomentosa extracts prevented the LPS-
dependent activation of specific NF-κB and AP-1 transcription factors in immune cells 
(Allen-Hall et al., 2010). Allen et al. (2017) has documented that THP-1 cells treated 
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with both U. tomentosa and 5–9 Gy ionizing radiation showed a strong reduction in cell 
proliferation and promoted caspase cleavage and DNA fragmentation in the cells. 
Furthermore, U. tomentosa extracts reduced the expression of Cyclin E and Cyclin B and 
reduced p38, ERK, and SAP/JNK kinase activation (Allen et al., 2017). Gurrola-Díaz et 
al. (2011) showed that aqueous U. tomentosa extracts enriched in alkaloids prevented 
Wnt-signaling activity in three different cancer cell lines including HeLa, HCT116, and 
SW480 cells, by decreasing the expression of the Wnt-target gene, c-Myc. They also 
found that treatment with extracts of U. tomentosa extracts enriched in alkaloids were 
more efficient at inhibiting Wnt-signaling activity than treatment with aqueous extracts 
(Gurrola-Díaz et al, 2011). 
Fazio et al. (2008) examined the effect of a hydroethanolic U. tomentosa extract 
against several cancer cell lines in vitro, including B16-BL6 (murine melanoma), K1735 
(amelanotic murine melanoma), HT29 (human colon carcinoma), A549 (human lung 
carcinoma), WEHI 164 (mouse fibrosarcoma), and LEC (mouse liver endothelial) cell 
lines. As well, the study tested the effect of the plant extracts on B16-BL6 melanoma cell 
growth and metastasis in the C57BL/6 mouse. Researchers showed that U. tomentosa did 
not observe a strong cytotoxic effect in the laboratory; however, it prevented tumor 
growth and metastasis in vivo. In addition, the plant suppressed tumor necrosis factor 
alpha (TNF-α), interleukin-6 (IL-6), nitric oxide (NO), and Nuclear factor kappa B (NF-
κB) activity in vitro (Fazio et al., 2008). 
Based on the previous studies conducted on U. tomentosa extracts in vitro and in 
vivo, this plant has been demonstrated to have extensive biological activities, including 
anti-oxidant, anti-cancer, anti-microbial, immunomodulatory, and anti-inflammatory 
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activities (Heitzman et al., 2005; Luna-Palencia et al., 2013). These features support the 
idea that this plant is an important molecular tool with significant therapeutic potential. 
Specifically, previous results in vitro showed that U. tomentosa extracts significantly 
inhibited cell proliferation and induced morphological changes in a variety of cancer cell 
lines, such as breast cancer cells MCF7, HL60, EBV-transformed B lymphoma cells, and 
human leukemia cells K562 (Sheng et al., 1998; Riva et al., 2001; Cheng et al., 2007).  
There are few studies showed that U. tomentosa extracts significantly blocked the 
proliferation of neoplastic cells in vivo (Fazio et al, 2008; Pilarski et al., 2010). However, 
there are insufficient data in the previous studies to describe the mechanism of U. 
tomentosa action on cancer cells. Therefore, U. tomentosa extracts will be tested against 
cancer cells in the current research using modern techniques in vitro and in vivo in order 
to investigate their effectiveness as possible pharmaceutical sources that could potentially 
generate different cancer therapeutic approaches. As well, these results are expected to 
provide valuable information concerning the molecular mechanisms by which this plant 
works against cancer cells. 
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1.12 Objectives and Experimental Summary 
The current study will be examined the ability of extracts of U. tomentosa to 
inhibit the growth and survival of cancer cells in vitro. Both 70% ethanol and PBS, pH 
7.4, extracts of U. tomentosa will be tested in order to evaluate their potential anticancer 
activity. Two cancer cell lines will be used in vitro, including the B16-BL6 mouse 
melanoma and 4T1 mouse breast cancer cells. In terms of molecular techniques, HPLC 
will be performed to characterize the alkaloids present in the U. tomentosa extracts and in 
various fractions. In addition, the ability of U. tomentosa to inhibit cell proliferation in 
vitro will be assessed using MTT cell proliferation assays (Methyl-Tetrazolium), and 
histochemistry using Ki-67 antigen detection. The ability of U. tomentosa to induce 
apoptosis in the cancer cells will be assessed using cell morphology, flow cytometery, 
and histochemistry with the TUNEL reagent.  
This study will also examine the effect of U. tomentosa on the growth and 
survival of cancer cells using the isogenic tumour transplantation model. The B16-BL6 
mouse melanoma cell line will also be used in the animal models. Specifically, tumours 
will be formed by subcutaneous injection of B16-BL6 cancer cell in the right flank of 
mice. The ability of U. tomentosa extracts to inhibit tumour growth in vivo will be tested 
by injecting extracts either intraperioneally or into the tumour and assessed by weighing 
and measuring tumour growth. Histological analysis of the tissues will be performed in 
order to evaluate the anti-cancer effects of U. tomentosa extracts in treated mice by 
measuring the level of the Ki-67 proliferation antigen and the amount of TUNEL-specific 
DNA fragmentation. Furthermore, changes in immune cell infiltration will be examined 
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using immunohistochemistry for various immune cell markers including CD3, CD4, 
CD8, ICAM-1, E - selectin, PECAM -1, Integrin αIIb, CD19, and CD45 in order to 
determine if the U. tomentosa extracts can affect the activation and tumour infiltration of 
immune cells. 
Together, these data are expected to elucidate the effects of extracts of this plant 
on the B16-BL6 and 4T1 cell death pathway, and to determine if pro-apoptotic 
mechanisms are activated in response to treatment with extracts of U. tomentosa in vitro 
and in vivo. In conclusion, the goal of this research is to determine if U. tomentosa can be 
developed into a reliable and effective treatment for cancer that may ultimately be 
suitable for human patients. 
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Chapter 2:  Uncaria tomentosa extracts were examined in vitro to 
measure the growth and survival of cancer cells (B16-BL6 and 4T1) 
2.1 Introduction 
U. tomentosa, commonly known as Cat’s Claw, has been used historically by the 
Asháninkas indigenous people for the treatment of a set of pathologies, including 
inflammations of the urinary tract and bone pain (Keplinger et al., 1999). Recently, U. 
tomentosa extracts have been tested for a variety of pharmacological applications, such as 
the treatment of Alzheimer’s, rheumatoid arthritis, respiratory infections, and several 
types of cancer (Zhang et al., 2015). U. tomentosa has been shown to have anticancer 
activity against a number of different cancer cell lines in the laboratory, such as breast 
cancer, leukemia, cervical carcinoma, and osteosarcoma (De Martino et al., 2006; Cheng 
et al., 2007). Aqueous extracts of U. tomentosa were also shown to suppress the growth 
of human neuroblastoma, glioma, MCF-7 breast cancer, and HL60 promyelocytic 
leukaemia cells (Sheng et al., 1998; Riva et al., 2001; Pilarski et al., 2007). 
Researchers have shown that different compounds derived from U. tomentosa 
extracts have activity against several cancer cells in vitro and in vivo. Different oxindole 
alkaloids, including isopteropodine, pteropodine, isomitraphylline, uncarine F, and 
mitraphylline isolated from ethanolic extracts of U. tomentosa were shown to inhibit the 
growth of several cancer cell lines including CCRF-CEM-C7H2 (human lymphoblastic 
leukaemia T cells) (Bacher et al., 2006), B16-BL6 (murine melanoma), K1735 
(amelanotic murine melanoma), HT29 (human colon carcinoma), A549 (human lung 
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carcinoma), WEHI 164 (mouse fibrosarcoma), and LEC (mouse liver endothelial) cell 
lines (Fazio et al., 2008). MTC cells treated with isopterpodine and pteropodine isolated 
from U. tomentosa showed remarkable pro-apoptotic properties; while treatment with 
alkaloid-poor fractions reduced cell proliferation but did not induce apoptosis (Rinner et 
al., 2009). The tetracyclic alkaloid-free aqueous extract of U. tomentosa showed 
cytotoxic effects against HepG2 cells but not non-malignant NHDF cells (Kośmider et 
al., 2017). Treatment with this extract promoted apoptosis, increased ROS production, 
and decreased NF-kB activation in HepG2 cells. 
Several different active compounds have been found in this plant, including 
alkaloids, polyphenols, and triterpene derivatives (De Martino et al., 2006; Keplinger et 
al., 1999). These bioactive compounds can be complementary or synergic in their actions 
to produce the effects of U. tomentosa extracts (Wirth and Wagner, 1997). Several 
studies showed that U. tomentosa extracts significantly reduced the production of 
cytokines, such as TNF-α and IL-6, from immune cells. As well, NF-κB activity was 
blocked by U. tomentosa extracts (Caballero et al., 2005; Fazio et al., 2008; Dreifuss et 
al., 2010). Further studies are required to describe underlying molecular mechanism of U. 
tomentosa. 
Generally, the overarching goal of this research is to shed light on the use of U. 
tomentosa as a new effective approach in the treatment of cancer. The present study 
assesses the efficacy of U. tomentosa extracts to block the growth and promote apoptosis 
in B16-BL6 and 4T1 breast cancer cells in vitro. Various methods were performed to 
characterize the anti-cancer ability of this plant. These methods included MTT assays, 
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immunohistochemistry, flow cytometry, and high-performance liquid chromatography 
(HPLC).  
Specifically, the MTT cell proliferation assay was performed to measure the 
changes in cell viability and proliferation rate in cells treated with U. tomentosa extracts. 
Immunohistochemistry was utilized to detect specific target antigens, in particular the Ki-
67 protein and TUNEL assay. The proliferation of cancer cells was examined following 
the treatment with U. tomentosa extracts using Ki67 proliferation marker which has been 
shown to label those cells that are actively proliferating. The TUNEL assay was used to 
detect DNA fragmentation in cancer cells treated with U. tomentosa extracts. Flow 
cytometry was also used to evaluate the presence of apoptotic cells in sub-G1 peaks for 
propidium iodide stained cells indicating the presence of subcellular fragmentation into 
apoptosomes. Finally, HPLC was performed to characterize the alkaloids found in the U. 
tomentosa extracts and also in different fractions used to treat the cancer cells. Together, 
these different methods were used in the laboratory in order to determine the effects of U. 
tomentosa extracts and their possible therapeutic applications that might be a potential 
source for the development of cancer drugs. 
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2.2 Materials and Methods 
2.2.1 Tissue culture 
The 4T1 cell line and the B16-BL6 cell line were obtained from ATCC [American 
Type Culture Collection, Manassas, VA] to be used in this research. The 4T1 cells were 
maintained in tissue culture plates (Sarstedt, Laval, QC) in Roswell Park Memorial 
Institute medium (RPMI, Fisher-Hyclone, Toronto, ON) supplemented with 10% fetal 
bovine serum (FBS, Fisher-Hyclone) 100 μg/ml streptomycin, and 100 U/ml penicillin 
(Invitrogen, Burlington, ON). The B16-BL6 cells were maintained in tissue culture plates 
in Dulbecco’s Modified Eagle Media (DMEM) supplemented with 10% FBS and 100 
μg/ml streptomycin, and 100 U/ml penicillin. The cells were incubated in a humidified 
atmosphere in a 5% CO2 incubator at 37 °C and subcultured 1:5 approximately every 2-3 
days for the 4T1 cells and every 3-4 days for the B16-BL6 cells. For experiments, the 
cells were treated with media including U. tomentosa extracts at various doses. All 
experiments were performed in triplicate for each assay. 
 
2.2.2 Uncaria tomentosa extracts  
U. tomentosa was obtained from Rosario Rojas (Lima, Peru) as a dried powder 
prepared from the bark or was purchased as a natural product supplement (Cat's Claw 
extract, Now Foods, Bloomington, IL. code 84618). The dried plant product was 
extracted with either PBS, pH7.4, or 70% ethanol and the soluble fraction used in the 
current research. For the preparation of the ethanolic extracts, 20 g of U. tomentosa 
powder was suspended in 200 ml 70% ethanol and heated to a slow boil with refluxing 
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for 1 hour. For the preparation of PBS extracts, 20 g of U. tomentosa powder was 
suspended in 180 ml water and 20 ml 10xPBS buffer and heated to a slow boil with 
refluxing for 1 hour. The mixture was allowed to cool and the bark debris was removed 
by centrifugation of the suspension at 2000 x g for 10 min. The supernatant was removed 
and filtered using a 0.22 μm syringe filter and then the extract was stored in aliquots at     
-80 °C. For both the animal experiments and the chemical fractionation experiments, the 
U. tomentosa extract supernatants were frozen and dried by lyophilization into a powder. 
The powder was weighed and resuspended in water immediately prior to use for the 
experiments. 
The 70% ethanol extract of U. tomentosa was fractionated over an ethanol 
gradient. For this experiment, 100 ml of 70% ethanol extract was freeze-dried and 
resuspended in 100 ml water. The resuspended U. tomentosa extract was applied to a 
polyvinylpolypyrollidone (PVPP) column and fractionated into multiple 100 ml fractions 
by increasing ethanol washes as follows; a water fraction, 20% ethanol fraction, 40% 
ethanol fraction, 60% ethanol fraction, 80% ethanol fraction, and 95% ethanol fraction. 
Each of the fractions was freeze-dried and resuspended in 70% ethanol at 10 mg/ml of 
dried powder. The PVPP fractions were analyzed by HPLC and examined for effects 
against the B16-BL6 and 4T1 cancer cell lines to evaluate cell growth using MTT assays 
and compared to both (ethanol and PBS) whole U. tomentosa extracts. 
 
2.2.3 Cell Treatments 
Both the B16-BL6 melanoma and 4T1 breast cancer cells were cultured in media 
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as described. For experiments, the cells were harvested by incubation in 0.25% trypsin, 
collected by centrifugation at 400 x g for 10 min, and resuspended in culture media at 
2x104 cells/ml. Then, the cells were plated on different culture substrates depending on 
the experiments: 100 µl of the cell suspensions were plated onto each well of a 96 well 
culture plate (i.e. 2000 cells/well); 1 ml of cell suspension was plated into each well of a 
24 well plate; or 2 ml of the cell suspension was plated on a 60 mm culture dish (i.e. 
4x104 cells/plate) and cultured overnight. On day 0 of the experiment, the cells were 
treated with culture media or various doses of either the alcoholic or PBS extracts of U. 
tomentosa suspended in the appropriate culture media containing 10% FBS and incubated 
at 37°C in 5% CO2. For the in vitro experiments, the cells were treated with 4 μg/ml, 20 
μg/ml, 40 μg/ml or 200 μg/ml of the U. tomentosa extract based on the weight of the 
original powdered root preparation prior to extraction. (The observation that the 
inhibitory effects of treatment with the various doses of the extract were highly 
reproducible suggests that the extraction process had a similar efficiency at extracting the 
active agents between multiple preparations.) The cells were treated with suspending 
media including the appropriate solvents at the same doses to generate negative controls. 
 
2.2.4 MTT assay (Methyl Tetrazolium Blue) 
The methyl thiazol tetrazolium (MTT) assay was performed to measure cell 
viability and proliferation rate in cells treated with the U. tomentosa extracts over the 
course of multiple days. The B16-BL6 or 4T1 cells were plated onto replicate 96-well 
plates, with one plate per day of experiment, and incubated overnight with 5% CO2 at 
37°C. The cells were treated in media containing FBS and various concentrations of U. 
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tomentosa extracts (control, 4 μg/ml, 20 μg/ml, 40 μg/ml or 200 μg/ml) on day 0. Each 
column of cells on the 96 well plate (n = 8) was treated with same conditions. The cells 
were incubated in the continued presence of the extracts over the course of 4 - 5 days 
without a media change. On each day of the experiment, one of the replica plates was 
treated by adding 10 μl of MTT solution in water into each well, at a final concentration 
of 0.25 mg/ml, and incubated for 4 hours. Following the incubation, the media was 
removed and 100 μl/well of dimethyl sulfoxide (DMSO) was added to solubilize the 
converted formazan crystals. The absorbance of each well was read at 540 nm using a 
(Spectramax 340PC 389) plate reader. Statistical analysis for the absorbance 
corresponding to each experimental condition for each day of the experiments was 
performed using an ANOVA using Graph Pad Prism Software.  
 
2.2.5 Cell Morphology 
This experiment examined the structure, shape, and appearance of both cancer cell 
lines. B16-BL6 melanoma cells or 4T1 breast cancer cells were plated on 24-well plates 
in culture media and incubated at 37°C for 24 hours. The cells were then treated with 
different doses of U. tomentosa extracted with 70% ethanol or PBS (control, 4 μg/ml, 40 
μg/ml, and 200 μg/ml). Micrographs of the cells were captured 24 hours, 48 hours, and 
72 hours after the treatment to evaluate the morphological responses to treatment using an 
Axiovert 100 Microscope and phase contrast optics (Zeiss Canada).  
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2.2.6 Fluorescence Immunohistochemistry for Ki-67 protein expression 
Ki-67 was used as a proliferation marker to assess whether the cancer cells were 
actively proliferating. B16-BL6 or 4T1 cells were plated on sterile glass coverslips in 6-
well plates in culture media overnight at 37◦C. These sterile glass cover slips were 
pretreated with HCl (2 N) for 1 hour and then washed with PBS, pH 7.4, to increase cell 
adhesion. The cells on the coverslips were treated with suspending media or with media 
containing 4 μg/ml, 20 μg/ml, 40 μg/ml or 200 μg/ml of U. tomentosa extracts and 
incubated for 24 hours, 48 hours, or 72 hours. Some cells were treated with 6 μg/ml of 
camptothecin for 24 hours, 48 hours, and 72 hours as a positive control for inhibition of 
cell proliferation. The treated cells were fixed by incubation with 4% formaldehyde 
(freshly prepared) in PBS, pH 7.4, for 5 minutes. The treated cells were then washed with 
PBS, pH 7.4, and permeabilized by incubation in 0.1% Triton X-100 in PBS, pH 7.4, at 
4°C for 5 min. The cells were blocked by incubation in 10% FBS, 0.5% BSA in PBS, pH 
7.4, overnight at 4°C. The cells were stained by incubation with 100 μl primary anti-Ki-
67 mouse monoclonal antibody (Santa Cruz Biotech., Santa Cruz, CA; titre 1:20) in 
blocking buffer for 60 minutes at room temperature. The primary antibody was removed 
and the coverslips were washed three times with PBS, pH 7.4. Then, the cells were 
incubated with 100 μl goat anti-mouse IgG, secondary antibody-FITC conjugate (green) 
(Santa Cruz Biotech.; titre 1:100) in blocking buffer for 60 minutes at room temperature. 
The secondary antibody- FITC was removed and the coverslips were washed three times 
with PBS, pH 7.4. Lastly, the coverslips were mounted on glass slides in 80% glycerol, 
sealed with nail polish, and images were captured using a fluorescence microscope (Zeiss 
Canada) for further analysis.  
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2.2.7 TUNEL assay (terminal deoxynucleotidyl transferase dUTP nick 
end labeling) 
The TUNEL assay was performed to detect DNA fragmentation by labeling the 
terminal end of nucleic acids through terminal deoxynucleotidyl transferase (TdT). This 
assay identifies individual cells undergoing apoptosis. B16-BL6 or 4T1 cells were grown 
on glass coverslips in culture media at 37°C overnight to allow sufficient time for the 
cells to adhere. These cells were then treated with suspending media or with 4 μg/ml, 40 
μg/ml, or 200 μg/ml of U. tomentosa extracts and incubated at 37°C for 24 hours, 48 
hours, or 72 hours. As a positive control for apoptosis, cells were treated with 6 mg/ml 
camptothecin for 24 hours, 48 hours, or 72 hours. The treated cells were fixed by 
incubation with 4% formaldehyde in PBS, pH 7.5 (freshly prepared) for 5 minutes and 
then permeabilized by incubation with 0.1% TritonX-100 in 0.1% sodium citrate (freshly 
prepared) for 5 min on ice. The cells were washed with PBS and treated with 50 μl/well 
TUNEL reaction mixture (Roche, Laval, QB) for a period of 60 minutes at room 
temperature. The coverslips were washed with PBS, pH 7.4, and mounted on glass slides 
in 80% glycerol.  Microscopic images were captured using an LSM510 fluorescence 
microscope (Zeiss Canada) for further analysis.  
 
2.2.8 Flow Cytometry 
Flow cytometry was performed to measure the DNA content in treated cell lines 
using the propidium iodide dye. The relative proportion of cells in the Sub-G1 (apoptosis 
peak), G1, S (DNA replication), and G2/M (cell checkpoint and mitotic phases) under the 
influence of U. tomentosa extracts was determined. 4T1 cells were grown in 60 x 15 mm 
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tissue culture plates in culture media containing FBS and incubated overnight at 37 °C. 
The cells were treated with U. tomentosa extract at concentrations of 4 μg/ml, 40 μg/ml 
or 200 μg/ml for a period of 24 hours and 48 hours. The 4T1 cells were also treated with 
6 μg/ml of camptothecin as a positive control for apoptosis. Cells were washed with PBS, 
pH 7.4, and harvested by incubation in 0.25% (w/v) trypsin-EDTA. Following that, the 
cells were collected by centrifugation at 400 x g for 10 min. Treated cells were fixed by 
incubation in 70% ethanol at -20ºC and stored for up to 2 weeks. On the day of staining, 
the cells were collected via centrifugation at 400 x g for 10 min and washed with PBS, 
pH 7.4.  These cell pellets were suspended in 500 μl of propidium iodide (PI) staining 
solution (150 mM NaCl, 0.1% Triton 100, 5.0 mg/ml RNase A, and 20 μg/ml of 
propidium iodide) and incubated for at least 30 min. Cell cycle analysis was performed 
using a Beckman Coulter LS600 flow cytometer and cell profiles created. The experiment 
was replicated for three different experimental days. 
 
2.2.9 High-performance liquid chromatography (HPLC) 
U. tomentosa root powder (1 g/10 ml) was extracted in 70% ethanol or PBS, pH 
7.4, by boiling for an hour. The supernatant was filtered through a 0.22 µm syringe filter 
and then analyzed by HPLC on a Breeze 2 chromatography system (Waters Inc., Toronto, 
ON).  In another experiment, the 70% ethanol extract of U. tomentosa was fractionated 
over an ethanol gradient and each fraction analyzed by HPLC. For this experiment, 100 
ml of 70% ethanol extract was freeze-dried and resuspended in 100 ml water. The 
resuspended U. tomentosa extract was applied to a polyvinylpolypyrollidone (PVPP) 
column and fractionated into multiple 100 ml fractions by increasing ethanol washes as 
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follows; a water fraction, 20% ethanol fraction, 40% ethanol fraction, 60% ethanol 
fraction, 80% ethanol fraction, and 95% ethanol fraction. Each of the fractions was 
freeze-dried and resuspended in 70% ethanol at 10 mg/ml of dried powder. The 
composition of each fraction was identified through HPLC.  
HPLC was performed on a Sunfire C18 column 3.5μm resin 4.6x100 mm. A 
gradient mobile phase was pumped onto the column at a flow rate of 1 ml/min. 
Specifically, the linear gradient was formed by mixing the solvents starting with 100% 
buffer A (60 volumes 10 mM phosphate buffer, pH 6.6, 20 volumes acetonitrile, and 20 
volumes methanol) and finishing with 100% B (30 volumes 10 mM phosphate buffer, pH 
6.6, 35 volumes acetonitrile, and 25 volumes methanol) over a period of 40 min. Then, 
100% buffer B were pumped onto the column for 10 min and lastly a gradient starting 
with 100% B and finishing with 100% A were pumped through the column for 5 min. 
The column was injected with a 5 µl aliquot of each sample at the beginning of each run. 
Finally, a wavelength of 245 nm was used to detect the components in the U. tomentosa 
extracts and peak area calculated to determine the relative amount of each component. 
Various peaks were identified by comparison to a series of standards, which had been 
previously shown to be present in U. tomentosa extracts following analysis of 1 mg/ml of 
each standard using the same conditions for HPLC characterization. These standards 
included uncarine D, mitraphylline, uncarine C, isomitraphyline, rhynophyline, and 
uncarine E (ChromaDex, Invine, CA). 
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2.3 Results 
2.3.1 The effect of U. tomentosa extracts on the proliferation of 4T1 
breast cancer and B16-BL6 melanoma cancer cells  
An MTT assay was performed to evaluate the effect of U. tomentosa extracts on 
the growth of 4T1 cells and B16-BL6 cells in vitro. Two different extracts of U. 
tomentosa were prepared, one in 70% ethanol and one in PBS, pH 7.4, and used to treat 
the cells over a period of four days. The results of these experiments indicated that cell 
viability decreased in a concentration-dependent manner when treated with U. tomentosa 
extracts.  
Treatment with U. tomentosa extracted with 70% ethanol showed no decrease in 
the growth of 4T1 cells at a low dose of 4 µg/ml, and a small effect when treated at the 
medium dose of 40 µg/ml. However, a complete inhibition in the growth of 4T1 cells was 
detected when treated with the highest dose of 200 µg/ml (Figure 2.1). In contrast, 
treatment of 4T1 cells with a PBS-extract of U. tomentosa was much less effective. 
Treatment with the low and medium doses of U. tomentosa extracted with PBS did not 
show any significant effect on 4T1 cell growth. Treatment with the high dose of U. 
tomentosa, 200 µg/ml, showed a significant inhibition of cell growth of approximately 
35% by day 4 of treatment (Figure 2.2).   
The B16-BL6 melanoma cells appeared to be somewhat more sensitive to U. 
tomentosa extracts than 4T1 cells. Treatment of B16-BL6 cells with the 70% ethanol 
extract for 4 days showed an approximately 10% decrease in cell number at the lowest 
concentration of 4 µg/ml and an approximately 80% decrease in cell number at the 
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medium dose of 40 µg/ml. Treatment with U. tomentosa extracted with ethanol at the 
highest dose of 200 µg/ml was able to effectively kill all of the B16-BL6 cells (Figure 
2.3). However, treatment with U. tomentosa extracted with PBS at the low and medium 
doses did not significantly inhibit the growth of B16-BL6 cells although treatment with 
the high dose greatly suppressed B16-BL6 cells by greater than 80% (Figure 2.4). These 
results showed that there were some differences in the sensitivity of the different cell 
lines (4T1 and B16-BL6) to U. tomentosa extracts in a dose-dependent manner. Further, 
treatment with U. tomentosa extracted with 70% ethanol had much stronger effects on 
both 4T1 cells and B16-BL6 cells compared to treatment with U. tomentosa extracted 
with PBS. 
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Figure 2.1 Effect of U. tomentosa extracted with ethanol on the growth 
of the 4T1 cell line 
4T1 breast cancer cells were treated with (A) 4 μg/ml, (B) 40 μg/ml, or (C) 200 
μg/ml of U. tomentosa extracted with 70% ethanol or control media on day 0 of treatment 
and cell number determined every day over a period of 4 days in order to measure cell 
growth. These treated cells were compared to control (untreated cells suspended in 
media) and cells treated with ethanol suspended in RPMI media. Relative cell number 
was determined for replica plates using the MTT assay and absorbance was determined 
every day at 450 nm. Data were analyzed for three independent experiments and 
significant differences confirmed by ANOVA * (P < 0.05). Graph pad prism was used for 
analysis. 
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Figure 2.2 Effect of U. tomentosa extracted with PBS on the growth of 
the 4T1 cell line 
4T1 breast cancer cells were treated with (A) 4 μg/ml, (B) 40 μg/ml, or (C) 200 
μg/ml of U. tomentosa extracted with phosphate-buffered saline, pH7.4, or control media 
on day 0 of treatment and cell number determined every day over a period of 4 days in 
order to measure cell growth. These treated cells were compared to control (untreated 
cells suspended in media) and cells treated with PBS, pH 7.4, suspended in RPMI media. 
Relative cell number was determined for replica plates using the MTT assay and 
absorbance was determined every day at 450 nm. Data were analyzed for three 
independent experiments and significant differences confirmed by ANOVA * (P < 0.05). 
Graph pad prism was used for analysis. 
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Figure 2.3 Inhibition of B16- BL6 cell proliferation treated with U. 
tomentosa extracted with ethanol 
B16-BL6 melanoma cells were treated with (A) 4 μg/ml, (B) 40 μg/ml, or (C) 200 
μg/ml) of U. tomentosa extracted with 70% ethanol or control media on day 0 of 
treatment and cell number determined every day over a period of 4 days. The treated cells 
were compared to control (untreated cells suspended in media) and cells treated with 
ethanol suspended in DMEM culture media. Relative cell number was determined for 
replica plates using the MTT assay and absorbance was determined every day at 450 nm.  
Data were analyzed for three independent experiments and differences were considered 
significant when p ≤ 0.05. 
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Figure 2.4 Inhibition of B16- BL6 cell proliferation treated with U. 
tomentosa extracted with PBS 
B16-BL6 melanoma cells were treated with (A) 4 μg/ml, (B) 40 μg/ml, or (C) 200 
μg/ml) of U. tomentosa extracted with phosphate-buffered saline, pH 7.4, or control 
media on day 0 of treatment and cell number determined every day over a period of 4 
days. The treated cells were compared to control (untreated cells suspended in media) and 
cells treated with PBS, pH 7,4, suspended in DMEM culture media. Relative cell number 
was determined for replica plates using the MTT assay and absorbance was determined 
every day at 450 nm. Data were analyzed for three independent experiments and 
differences were considered significant when p ≤ 0.05. 
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2.3.2 Cell morphology 
The effect of treatment with U. tomentosa extracts on cell morphology was tested 
using phase contrast microscopy. 4T1 breast cancer cells were treated with U. tomentosa 
extracted with ethanol or PBS to evaluate the cell morphology over a period of two days. 
Cells treated with the lowest dose of the ethanol extract (4 μg/ml) did not significantly 
change in size or shape. Treatment of the 4T1 cells with the medium dose (40 μg/ml) of 
the U. tomentosa ethanol extract showed an increase in the number of rounded cells and a 
lower cell density of cells compared to control cells, in particular after two days of 
treatment.  4T1 cells treated with the highest dose of the U. tomentosa ethanol extract 
(200 μg/ml) showed a significant increase in the number of rounded and atrophied cells, 
as well as a huge reduction in the total number of surviving 4T1 cells (Figure 2.5). The 
morphological changes in these cells included changes in number, shape, and structure of 
the cells. On the other hand, cells were treated with U. tomentosa extracted with PBS 
showed much less obvious morphological changes even when the cells were treated with 
the highest dose of the extract for 2 days. In contrast to the high dose, cells treated with 
low doses of the PBS extracts showed a relatively low frequency of rounded or atrophied 
cells compared to control (Figure 2.6). 
B16-BL6 cells were treated with different concentrations of U. tomentosa extracts 
and changes in cell morphology were examined over the course of four days using phase 
contrast microscopy. Treatment of B16-BL6 cells with the ethanol extract of U. 
tomentosa showed dose- and time-dependent changes in cell morphology. Cells treated 
with the low dose showed a decreased cell density over the course of the four days of 
treatment although the shape and size of the cells were similar to media-treated controls. 
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An increase in the frequency of atrophied cells was observed following the treatment with 
the medium dose of the U. tomentosa ethanol after four days and a complete atrophy of 
the cells was found when they were treated with the highest dose (Figure 2.7). Treatment 
with the highest dose of the ethanol extract of U. tomentosa for 3-4 days completely 
destroyed the cells as determined by phase contrast microscopy.  Furthermore, B16-BL6 
cells treated with PBS extract of U. tomentosa also showed significant dose- and time-
dependent changes in cell morphology (Figure 2.8). Cells treated with the low and 
medium doses of the extract showed some increase in cell rounding but very little change 
in cell density. However, cells treated with the highest dose of the PBS extract of U. 
tomentosa for 3-4 days showed significant decreases in cell number and increased 
atrophied cells. Taken together, these data show that treatment with the ethanol extract at 
high doses caused a marked atrophy in both the 4T1 cells and B16-BL6 cell lines and 
decreased the number of cells. However, treatment with the PBS extract, promoted 
significant atrophy in the B16-BL6 cells treated with the highest dose, but relatively little 
change was recorded in the 4T1 cells. 
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Figure 2.5 Effect of U. tomentosa ethanol extract on the morphology of 
the 4T1 cell line 
4T1 cells were plated on 6 well plates and treated with culture media (control) or 
4 μg/ml (low dose), 40 μg/ml (medium dose), or 200 μg/ml (high dose) of U. tomentosa 
extracted with 70% for 24 hours or 48 hours. Micrographs of random fields were 
obtaining using phase contrast optics using an Axiovert 100 microscope and Northern 
Eclipse Software and representative images shown. 
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Figure 2.6 Effect of U. tomentosa PBS extract on the morphology of the 
4T1 cell line 
4T1 cells were plated on 6 well plates and treated with culture media (control) or 
various doses  4 μg/ml (low dose), 40 μg/ml (medium dose), or 200 μg/ml (high dose) of 
U. tomentosa extracted with phosphate-buffered saline for 24 hours or 48 hours. 
Micrographs of random fields were obtaining using phase contrast optics using an 
Axiovert 100 microscope and Northern Eclipse Software and representative images 
shown. 
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Figure 2.7 Effect of U. tomentosa ethanol extract on the morphology of 
the B16-BL6 cell line 
B16-BL6 cells were plated on 6 well plates and treated with culture media 
(control) or various doses  4 μg/ml (low dose), 40 μg/ml (medium dose), or 200 μg/ml 
(high dose) of U. tomentosa extracted with 70% ethanol for 1, 2, 3, and 4 days. 
Micrographs of random fields were obtaining using phase contrast optics using an 
Axiovert 100 microscope and Northern Eclipse Software and representative images from 
three independent experiments is shown.  
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Figure 2.8 Effect of U. tomentosa PBS extract on the morphology of the 
B16-BL6 cell line 
B16-BL6 cells were plated on 6 well plates and treated with culture media 
(control) or various doses  4 μg/ml (low dose), 40 μg/ml (med dose), or 200 μg/ml (high 
dose) of U. tomentosa extracted with PBS, pH7.4, for 1, 2, 3, and 4 days. Micrographs of 
random fields were obtaining using phase contrast optics using an Axiovert 100 
microscope and Northern Eclipse Software and representative images from three 
independent experiments is shown.  
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2.3.3 Inhibition of the proliferation of cancer cells (4T1 and B16-BL6) 
using Ki-67 protein expression 
The expression levels of the Ki-67 proliferation nuclear antigen in cultured 4T1 
cells was evaluated after treatment of the cells with suspending media or U. tomentosa 
extracted with ethanol or PBS for 24 hours and 48 hours. The expression of the Ki-67 
antigen in the nuclei of cells is associated with active cell proliferation both in vitro and 
in vivo. Therefore, staining with the primary antibody was used to determine the growth 
fraction of an Uncaria-treated cell population. For these experiments, an FITC-labeled 
secondary antibody was used for detection. The stained cell cultures were examined using 
a fluorescence microscope and each experiment was performed three times on 3 separate 
days. Images of camptothecin-treated cells were after 48 h of treatment as a control for 
the lack of cell proliferation. The results of these studies showed treatment with U 
tomentosa extracts were able to reduce the expression of Ki-67 in a dose-, time- and 
extract-dependent manner. Specifically, treatment of 4T1 cells with the highest dose of U. 
tomentosa extracted with ethanol significantly blocked the expression Ki-67 at both 24 
and 48 h post-treatment (Figure 2.9 and 2.10). Treatment of 4T1 cells with the medium 
dose of the U. tomentosa ethanol extract for 24 hours showed a slight inhibition in the 
expression Ki-67 and treatment for 48 hours showed a more significant reduction in the 
expression of Ki-67.  
On the other hand, 4T1 cells treated with the highest dose of U. tomentosa 
extracted with PBS for 24 h did not show a significant amount of inhibition in the 
expression Ki-67 (Figure 2.11) but treatment with the extract for 48 hours did show a 
small decrease in Ki-67 staining (Figure 2.12).  
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The ability of treatment with U. tomentosa extracts to inhibit Ki-67 staining in a 
dose- time-, and extract-dependent manner was also seen for B16-BL6 mouse melanoma 
cells. Figures 2.13 and 2.14 shows the results of B16-BL6 cancer cells treated with U. 
tomentosa extracts for 72 hours. The expression of Ki-67 was significantly inhibited in 
B16-BL6 cells after treatment with high doses of U. tomentosa extracted with ethanol 
(Figure 2.13). Treatment with the medium dose of the ethanol extract of U. tomentosa 
partially inhibited the number of cells that stained with the Ki-67 antibody while low 
doses of the ethanol extract did not significantly inhibit Ki-67 expression. Treatment of 
B16-BL6 cells with the highest dose of U. tomentosa extracted into PBS resulted in a 
small reduction in the staining with Ki67 while treatment with both the medium and low 
doses did not significantly decrease Ki-67 staining (Figure 2.14). These results are 
consistent with the results from the cell viability experiments. Overall, treatment with U. 
tomentosa extracted with ethanol showed the strongest reduction in the number of Ki-67- 
positive cells in both cell lines (4T1 cells and B16-BL6 cells), consistent with the 
decreases in cell number. Further, treatment of the cells with U. tomentosa extracted with 
PBS had a much weaker effect on inhibiting the number of Ki-67-positive cells 
corresponding to a weaker effect on inhibiting cell proliferation. 
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Figure 2.9 Effect of U. tomentosa extracted with ethanol on 4T1 cell 
proliferation 
4T1 cells were plated on glass coverslips and treated with suspending media (A, 
control) and low (B, 4 µg/ml), medium (C, 40 µg/ml) and high (D, 200 µg/ml) doses of 
U. tomentosa extracted with ethanol for 24 hours. To measure the cell proliferation index, 
treated 4T1 cells were stained by incubation with the anti-Ki-67 primary antibody and 
then detected by staining with an FITC-labeled secondary antibody. The monolayers 
were analyzed using a fluorescence microscope and representative photos taken.  
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Figure 2.10 Effect of U. tomentosa extracted with ethanol on 4T1 cell 
proliferation 
4T1 cells were plated on glass coverslips and treated with suspending media (A, 
control) and low (B, 4 µg/ml), medium (C, 40 µg/ml) and high (D, 200 µg/ml) doses of 
U. tomentosa extracted with ethanol for 48 hours. The cells were also treated with 6 
μg/ml of camptothecin (E) as a positive control for cell death. To measure the cell 
proliferation index, treated 4T1 cells were stained by incubation with the anti-Ki-67 
primary antibody and then detected by staining with an FITC-labeled secondary antibody. 
The monolayers were analyzed using a fluorescence microscope and representative 
photos taken   
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Figure 2.11 Effect of U. tomentosa extracted with PBS on 4T1 cell 
proliferation 
4T1 cells were plated on glass coverslips and treated with suspending media (A, 
control) and low (B, 4 µg/ml), medium (C, 40 µg/ml) and high (D, 200 µg/ml doses of U. 
tomentosa extracted with PBS for 24 hours. Also, cells were treated with culture media as 
a negative control. To measure the cell proliferation index in treated 4T1 cells, the 
coverslips were stained by incubation with the anti-Ki-67 primary antibody and then 
detected by staining with an FITC-labeled secondary antibody. The monolayers were 
analyzed using a fluorescence microscope and representative photos taken.   
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Figure 2.12 Effect of U. tomentosa extracted with PBS on 4T1 cell 
proliferation 
4T1 cells were plated on glass coverslips and treated with suspending media (A, 
control) and low (B, 4 µg/ml), medium (C, 40 µg/ml) and high (D, 200 µg/ml doses of U. 
tomentosa extracted with PBS for 48 hours. The cells were also treated with 6 μg/ml of 
camptothecin (E) as a positive control for cell death. To measure the cell proliferation 
index in treated 4T1 cells, the coverslips were stained by incubation with the anti-Ki-67 
primary antibody and then detected by staining with an FITC-labeled secondary antibody. 
The monolayers were analyzed using a fluorescence microscope and representative 
photos taken.  
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Figure 2.13 Effect of U. tomentosa extracted with ethanol on B16-BL6 
cell proliferation 
B16-BL6 cells were plated on tissue culture plates and treated with suspending 
media (A, control) and low (B, 4 µg/ml), medium (C, 40 µg/ml) and high (D, 200 µg/ml) 
doses of U. tomentosa extracted with 70% ethanol for 72 hours. To measure the cell 
proliferation index in treated B16-BL6 cells, the cells were stained by incubation with the 
anti-Ki-67 primary antibody and then detected by staining with an FITC-labeled 
secondary antibody. The monolayers were analyzed using a fluorescence microscope and 
representative photos taken. Images show the fluorescence channel (excitation at 488 nm 
and emission at 520 nm), phase contrast channel, and the combination. 
 
  
 81 
 
 
  
 82 
 
 
 
 
 
Figure 2.14 Effect of U. tomentosa extracted with PBS on B16-BL6 cell 
proliferation 
B16-BL6 cells were plated on tissue culture plates and treated with suspending 
media (A, control) and low (B, 4 µg/ml), medium (C, 40 µg/ml) and high (D, 200 µg/ml) 
doses of U. tomentosa extracted with PBS, pH 7.4, for 72 hours. To measure the cell 
proliferation index in treated B16-BL6 cells, the cells were stained by incubation with the 
anti-Ki-67 primary antibody and then detected by staining with an FITC-labeled 
secondary antibody. The monolayers were analyzed using a fluorescence microscope and 
representative photos taken. Images show the fluorescence channel (excitation at 488 nm 
and emission at 520 nm), phase contrast channel, and the combination. 
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2.3.4 Detection of DNA fragmentation in 4T1 cells and B16-BL6 cells 
treated with U. tomentosa extracts  
A TUNEL assay was performed to detect DNA fragmentation in cell cultures 
treated with U. tomentosa extracts. DNA fragmentation is considered a critical hallmark 
of apoptosis. 4T1 cells were treated with various doses of either the ethanol or PBS 
extracts of U. tomentosa for a period of 24 hours and 48 hours and then analyzed using a 
TUNEL reagent kit based on the ability of terminal transferase to add a fluorescently 
labelled oligonucleotide to free DNA ends. Fluorescence microscopy (Olympus IX3) was 
used to measure the level of fluorescence corresponding to nucleotide incorporation and 
experiments were performed three times. Images of camptothecin-treated cells were taken 
during the treatment of 48 hours as a positive control for increased apoptosis. Treatment 
of 4T1 cells with the highest dose of U. tomentosa ethanol extract for 24 hours and 48 
hours clearly showed TUNEL staining in the majority of the cells that remained alive 
(Figure 2.15, and 2.16). Cells treated with the medium dose of U. tomentosa ethanolic 
extract for 24 hours showed a low level of TUNEL staining associated with cell death 
(Figure 2.15) but treatment for 48 hours, caused a significant increase in DNA 
fragmentation (Figure 2.16). On the other hand, no significant staining for the TUNEL 
reagent was observed in 4T1 cells treated with U. tomentosa extracted with PBS at the 
highest dose for 24 hours (Figure 2.17). However, TUNEL staining was observed in 
some cells when the treatment period was extended to 48 hours (Figure 2.18). Treatment 
with the PBS extract of U. tomentosa at the low and medium doses did not promote any 
significant TUNEL staining in cells treated for either 24 hours or 48 hours.  
TUNEL staining of the B16-BL6 cells treated with U. tomentosa extract showed 
similar results to the 4T1 cells. Specifically, the level of TUNEL staining in B16-BL6 
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cells was assayed after 24 hours and 72 hours of treatment with U. tomentosa extracts. A 
significant increase in the proportion of apoptotic cells was observed after treatment with 
the high dose of U. tomentosa extracted with ethanol, at both the 24 hour and 72 hour 
treatments (Figure 2.19 and 2.20). Treatment of B16-BL6 cells with the low dose of U. 
tomentosa extracted with ethanol did not show any increase in TUNEL staining after 24 h 
but almost all of the cells were labeled after treatment for 72 hours. However, the level of 
TUNEL staining that was detected after treatment with the high dose of U. tomentosa 
extracted with PBS for 24 hours was not detected while treatment for 72 hours promoted 
staining in some of the cells (Figure 2.21, and 2.22). Treatment with the low dose of U. 
tomentosa extracted with PBS, pH 7.4, did not promote TUNEL staining. Overall, 
treatment of U. tomentosa extracted with ethanol significantly induces apoptosis in both 
cell lines (4T1 cells and B16-BL6 cells) to a greater extent than treatment with U. 
tomentosa extracted with PBS correlating with the cell proliferation results. 
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Figure 2.15 Detection of DNA fragmentation in 4T1 cells treated with U. 
tomentosa extracted with ethanol using the TUNEL assay for 24 hours 
4T1 cells were plated on glass coverslips and treated with suspending media (A, 
control) and low (B, 4 µg/ml), medium (C, 40 µg/ml) and high (D, 200 µg/ml) doses of 
U. tomentosa extracted with ethanol for 24 hours. Cells were stained by incubation with 
50 μl/well TUNEL reaction mixture to detect free DNA ends (DNA fragmentation). The 
monolayers were analyzed using a fluorescence microscope and representative photos 
taken. Images show the fluorescence channel (excitation at 488 nm and emission at 520 
nm), phase contrast channel, and the combination. 
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Figure 2.16 Detection of DNA fragmentation in 4T1 cells treated with U. 
tomentosa extracted with ethanol using the TUNEL assay for 48 hours 
4T1 cells were plated on glass coverslips and treated with suspending media (A, 
control) and low (B, 4 µg/ml), medium (C, 40 µg/ml) and high (D, 200 µg/ml) doses of 
U. tomentosa extracted with 70% ethanol for 48 hours. Cells were stained by incubation 
with 50 μl/well TUNEL reaction mixture to detect free DNA ends (DNA fragmentation). 
The monolayers were analyzed using a fluorescence microscope and representative 
photos taken. Images show the fluorescence channel (excitation at 488 nm and emission 
at 520 nm), phase contrast channel, and the combination. 
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Figure 2.17 Detection of DNA fragmentation in 4T1 cells treated with U. 
tomentosa extracted with PBS using the TUNEL assay for 24 hours 
4T1 cells were plated on glass coverslips and treated with suspending media (A, 
control) and low (B, 4 µg/ml), medium (C, 40 µg/ml) and high (D, 200 µg/ml) doses of 
U. tomentosa extracted with PBS, pH 7.4, for 24 hours. Cells were stained by incubation 
with 50 μl/well TUNEL reaction mixture to detect free DNA ends (DNA fragmentation). 
The monolayers were analyzed using a fluorescence microscope and representative 
photos taken. Images show the fluorescence channel (excitation at 488 nm and emission 
at 520 nm), phase contrast channel, and the combination. 
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Figure 2.18 Detection of DNA fragmentation in 4T1 cells treated with U. 
tomentosa extracted with PBS using the TUNAL assay for 48 hours 
4T1 cells were plated on glass coverslips and treated with suspending media (A, 
control) and low (B, 4 µg/ml), medium (C, 40 µg/ml) and high (D, 200 µg/ml) doses of 
U. tomentosa extracted with PBS, pH 7.4, for 48 hours. Cells were stained by incubation 
with 50 μl/well TUNEL reaction mixture to detect free DNA ends (DNA fragmentation). 
The monolayers were analyzed using a fluorescence microscope and representative 
photos taken. Images show the fluorescence channel (excitation at 488 nm and emission 
at 520 nm), phase contrast channel, and the combination. 
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Figure 2.19 Detection of cell death in B16-BL6 cells treated with U. 
tomentosa extracted with ethanol using the TUNEL assay for 24 hours 
B16-BL6 cells were plated on glass coverslips and treated with suspending media 
(A, control) and low (B, 4 µg/ml), and high (D, 200 µg/ml) doses of U. tomentosa 
extracted with 70% ethanol for 24 hours. Cells were stained by incubation with 50 μl/well 
TUNEL reaction mixture to detect free DNA ends (DNA fragmentation). The monolayers 
were analyzed using a fluorescence microscope and representative photos taken. Images 
show the fluorescence channel (excitation at 488 nm and emission at 520 nm), phase 
contrast channel, and the combination. 
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Figure 2.20 Detection of cell death in B16-BL6 cells treated with U. 
tomentosa extracted with ethanol using the TUNAL assay for 72 hours 
B16-BL6 cells were plated on glass coverslips and treated with suspending media 
(A, control) and low (B, 4 µg/ml), and high (C, 200 µg/ml) doses of U. tomentosa 
extracted with 70% ethanol for 72 hours. Cells treated with 6 mg/ml camptothecin for 72 
h (D) were used as a positive control for apoptosis. Cells were stained by incubation with 
50 μl/well TUNEL reaction mixture to detect free DNA ends (DNA fragmentation). The 
monolayers were analyzed using a fluorescence microscope and representative photos 
taken. Images show the fluorescence channel (excitation at 488 nm and emission at 520 
nm), phase contrast channel, and the combination. 
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Figure 2.21 Detection of cell death in B16-BL6 cells treated with U. 
tomentosa extracted with PBS using the TUNEL assay for 24 hours 
B16-BL6 cells were plated on glass coverslips and treated with suspending media 
(A, control) and low (B, 4 µg/ml), and high (C, 200 µg/ml) doses of U. tomentosa 
extracted with PBS, pH 7.4, for 24 hours. Cells were stained by incubation with 50 
μl/well TUNEL reaction mixture to detect free DNA ends (DNA fragmentation). The 
monolayers were analyzed using a fluorescence microscope and representative photos 
taken. Images show the fluorescence channel (excitation at 488 nm and emission at 520 
nm), phase contrast channel, and the combination. 
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Figure 2.22 Detection of cell death in B16-BL6 cells treated with U. 
tomentosa extracted with PBS using the TUNEL assay for 72 hours 
B16-BL6 cells were plated on glass coverslips and treated with suspending media 
(A, control) and low (B, 4 µg/ml), and high (C, 200 µg/ml) doses of U. tomentosa 
extracted with PBS, pH 7.4, for 72 hours. Cells treated with 6 µg/ml camptothecin for 72 
h (D) were used as a positive control for apoptosis. Cells were stained by incubation with 
50 μl/well TUNEL reaction mixture to detect free DNA ends (DNA fragmentation). The 
monolayers were analyzed using a fluorescence microscope and representative photos 
taken. Images show the fluorescence channel (excitation at 488 nm and emission at 520 
nm), phase contrast channel, and the combination. 
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2.3.5 Detection of 4T1 cell accumulation in sub-G1 using flow cytometry 
Flow cytometry was conducted to investigate the effect of treatment with U. 
tomentosa extracts on 4T1 cell cycle distribution and the presence of sub-G1 apoptotic 
cells. In these experiments, cells were treated with low (4 µg/ml), medium (40 µg/ml) and 
high (200 µg/ml) doses of U. tomentosa extracted with either ethanol or PBS for 24 hours 
and 48 hours. These cells were stained with propidium iodide (PI) dye to measure the 
amount of DNA in each cell. Treatment of the 4T1 cells with the high dose of the ethanol 
extract of U. tomentosa for 24 hours and 48 hours induced a large increase in the 
percentage of the cells in the sub-G1 peak indicating a large increase in apoptosis. In 
particular, the treatment during 48 hours at the highest dose showed a huge increase in 
sub-G1 cells, which increased to 78.4 % while the treatment during 24 hours increased 
the sub-G1 population to 61.9 % (Figure 2.23). This is similar to the effect of treatment 
with camptothecin, which was used as a positive control to promote formation of 
apoptotic cells and showed an increase to 74.9% of the cells in the sub-G1 peak (Figure 
2.23). Treatment with the medium dose of the ethanol extract of U. tomentosa for 24 
hours did not have a large affect the number of cells in different phases of the cell cycle 
although there was a small increase in the number of cells in the sub-G1 peak. After 
treatment for 48 hours, treatment with the medium dose significantly increased the 
number of cells in the sub-G1 peak and decreased the number of cells in G2/M. 
Treatment with the low dose of the ethanol extract of U. tomentosa for 24 or 48 hours did 
not significantly alter the number of cells in the different phases of the cell cycle and did 
not increase the number of cells in the sub-G1 peak.  
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On the other hand, the treatment of 4T1 cells with U. tomentosa extracted with 
PBS, pH 7.4, was less active. Treatment of 4T1 cells with the high dose of U. tomentosa 
extracted with PBS, pH 7.4, promoted a small increase in the number of cells in the sub-
G1 phase from 5.0% to 11.9 % after 24 hours, and to 13.8% after treatment for 48 hours 
(Figure 2.24). Treatment with the low and medium doses of U. tomentosa extracted with 
PBS, pH 7.4, did not significantly alter the cell cycle pattern from the untreated control. 
Together, the results of the flow cytometry confirmed the findings of previous 
experiments that U. tomentosa extracted with ethanol can significantly induce apoptosis 
in 4T1 cells more effectively than U. tomentosa extracted with PBS. 
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Figure 2.23 Effect of U. tomentosa extracted with ethanol on cell cycle 
profiles (sub-G1 peaks) in 4T1 cells 
To confirm apoptosis in 4T1 cells treated with U. tomentosa, flow cytometry 
analysis was applied. Cells were grown in 60 x 15 mm tissue culture plates and treated 
with suspending media (control), and low (4 µg/ml), medium (40 µg/ml), and high (200 
µg/ml) doses of U. tomentosa extracted with ethanol over a period of 24 hours and 48 
hours. Camptothecin was used as a positive control during the treatment for 48 hours. 
The cells were incubated with propidium iodide and analysis was performed using a 
Beckman Coulter LS600 flow cytometer. The experiments were run in triplicate. The 
histogram displayed the percentage of cells in the Sub-G1 (apoptotic cells) and other 
phases of the cells cycle and the table of percentages in each phase are the means for the 
3 replicates. 
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Figure 2.24 Effect of U. tomentosa extracted with PBS on cell cycle 
profiles (sub-G1 peaks) in 4T1 cells 
To confirm apoptosis in 4T1 cells treated with U. tomentosa, flow cytometry 
analysis was applied. Cells were grown in 60 x 15 mm tissue culture plates and treated 
with suspending media (control), and low (4 µg/ml), medium (40 µg/ml) and high (200 
µg/ml) doses of U. tomentosa extracted with PBS, pH7 .4, over a period of 24 hours and 
48 hours. The cells were incubated with propidium iodide and analysis was performed 
using a Beckman Coulter LS600 flow cytometer. The experiments were run in triplicate. 
The histogram displayed the percentage of cells in the Sub-G1 (apoptotic cells) and other 
phases of the cells cycle and the table of percentages in each phase are the means for all 3 
replicates. 
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2.3.6 HPLC analysis of U. tomentosa extracts and fractions and their 
effect on cell growth 
U. tomentosa was extracted in 70% ethanol or PBS, pH 7.4. Ground bark was 
suspended in 70% ethanol or PBS, pH 7.4, at a concentration of 0.1 mg/ml and boiled 
with refluxing for a period of one hour. Bark residue was removed by centrifugation and 
the supernatant filtered through 0.22 µm filters for use in experiments. This filtrate was 
also subjected to analysis by HPLC on a C18 column using a gradient mobile phase 
comprised of 10 mM phosphate buffer, pH 6, acetonitrile, methanol buffer (60/20/20 to 
20/35/25 over 40 min) at 1 ml/min. Peaks corresponding to components of the U. 
tomentosa were detected at a wavelength of 245 nm as indicated in Figure 2.25. 
Molecular standards corresponding to the known components of the U. tomentosa 
extracts including the alkaloids, uncarine D, mitraphylline, uncarine C, isomitraphyline, 
rhynophyline, and uncarine F, were subjected to analysis using the same conditions on 
the same day and were used to identify the peaks present in the extracts. Results indicated 
the presence of a significant amount of these alkaloids in the ethanol extract of U. 
tomentosa, while a lower amount of these alkaloids was present in the PBS extract. 
Analysis of the area under each of the absorbance peaks suggests that, on average, there 
is about tenfold less of each of the alkaloids in the PBS extract compared to the alcohol 
extract. 
The U. tomentosa extracts were fractionated into different components in order to 
enrich for the potential active molecules and then tested for activity by measuring their 
effect on the proliferation of both 4T1 and B16-BL6 cells. In this experiment, 200 ml of a 
70% ethanol extract of U tomentosa was freeze-dried and resuspended in 20 ml water. 
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The resuspended U. tomentosa ethanol extract was then applied to a 50 ml 
polyvinylpyrrollidone (PPVP) column equilibrated in water. The extract was eluted from 
the column using 4 volumes each of water, 20% ethanol, 40% ethanol, 60% ethanol, 80% 
ethanol, and 95% ethanol. Each of these fractions was lyophilized, combined for each 
elution, and resuspended in 70% ethanol at 10 mg/ml final concentration. The 
composition of each of the fractions was analyzed using HPLC as indicated in Figure 
2.26. This analysis shows that the level of the various indolalkaloids was different in each 
of the PVPP fractions of U. tomentosa. The highest concentrations of the alkaloids were 
in the 40% ethanol fraction. 
The effect of these, five different fractions on cell growth was examined against 
both the 4T1 and B16-BL6 cell lines, using MTT assays (Figure 2.27). Cells were treated 
with 1 µg/ml of the reconstituted fraction in culture media on day 0 and cell numbers 
were determined over 3 to 4 days in the continued presence of the extract. Interestingly, 
the results were somewhat different between the B16-BL6 and 4T1 cells. For the 4T1 
cells, treatment with the 80% ethanol fraction showed the strongest inhibition of cell 
growth while treatment with the 60% ethanol fraction significantly inhibited cell 
proliferation.  For the B16-BL6 cells the results showed that the 60% ethanol fraction had 
the strongest inhibitory effect while the 80% ethanol fraction was able to significantly 
inhibit cell proliferation using the MTT assay. 
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Figure 2.25. Analysis of U. tomentosa extracts using HPLC  
U. tomentosa was extracted in 70% ethanol or PBS followed by boiling over a 
period of one hour. HPLC was performed for the filtrate on a C18 column. For detection, 
a wavelength of 245 nm was used. The peaks were identified by comparison to the 
elution of standards for U. tomentosa under the same conditions on the same day: (1) 
uncarine D, (2) mitraphylline, (3) uncarine C, (4) isomitraphyline, (5) rhynophyline, and 
(6) uncarine E.  
 
  
 111 
 
 
  
 112 
 
 
 
 
 
Figure 2.26. Analysis of U. tomentosa extracts fractionated by PVPP 
column chromatography using HPLC 
Another experiment was performed by drying 70% ethanol extract and suspended 
in water. Then, U. tomentosa extracted with 70% ethanol was fractionated by PPVP 
column with increasing ethanol washes and analyzed through HPLC. The peaks were 
identified by comparison to the elution of standards for U. tomentosa under the same 
conditions on the same day: (1) uncarine D, (2) mitraphylline, (3) uncarine C, (4) 
isomitraphyline, (5) rhynophyline, and (6) uncarine E. 
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Figure 2.27. Effect of U. tomentosa fractions on cell proliferation 
MTT assay was performed in vitro experiments to evaluate the effect of various 
fractions of U. tomentosa on the growth of A. 4T1 cells or B. B16-BL6 cells. These 
fractions (water fraction, 20% ethanol fraction, 40% ethanol fraction, 60% ethanol 
fraction, and 80% ethanol fraction) were individually tested against 4T1 breast cancer 
cells or B16-BL6 cells at a dose (10 ul) over a period of 3 to 4 days. Then, treated cells 
were compared to the control (untreated cells suspended in media). Data were analyzed 
for three independent experiments and significant differences confirmed by ANOVA * (P 
< 0.05). Graph pad prism was used for analysis. 
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2.4 Discussion 
2.4.1 Identification of Uncaria tomentosa 
U. tomentosa has a significant potential as a medicinal natural product because it 
contains several key active components, such as alkaloids, triterpenes, and polyphenols 
(Zhang et al., 2015, Navarro-Hoyos et al., 2015, 2018). There are approximately 50 
compounds that have been separated and characterized from extracts of this species. It is 
noteworthy that a number of these components, about 30 chemical markers, appear to be 
unique to this species of plants (Navarro-Hoyos et al., 2015, 2018). Additionally, the 
importance of this plant is supported by the fact that several studies have already revealed 
a broad range of biological activities, like antioxidant, anti-inflammatory, 
immunomodulatory, antidiabetic, and anticancer properties (Heitzman et al., 2005; Zhang 
et al., 2015).   
Although many studies have suggested that a group of alkaloids are responsible 
for the health effects of U. tomentosa, some studies imply that these health effects might 
be accredited to a synergistic interaction between multiple ingredients found in the 
extracts (Falkiewicz and Lukasiak, 2001). Furthermore, studies have shown that the 
polyphenol fractions have strong effects on many molecular mechanisms. For example, it 
has been demonstrated that polyphenols are able to modulate pathways connected to 
chronic inflammation and energy metabolism (Funes et al., 2010; Hernandez-Aguilera et 
al, 2013). 
Navarro-Hoyos et al. (2018) have studied the polyphenolic constituents found in 
both the aqueous and ethanolic extracts of U. tomentosa bark and leaves. High amounts 
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of the total phenolics and proanthocyanidins were found in the leaves and were shown to 
contain antioxidant activity. Researchers identified 32 ingredients among the phenolics 
and proanthocyanidins, including hydroxycinnamic acids, hydroxybenzoic acids, flavan-
3-ol monomers, procyanidin dimers and trimers, flavalignans–cinchonains, and 
propelargonidin dimers (Navarro-Hoyos, et al., 2015, 2018). One of the main bioactive 
compounds of U. tomentosa is the pentacyclic oxindole alkaloid, mitraphylline. It has 
been shown that mitraphylline has potent anticancer activity against human sarcoma 
and breast cancer cells (García Giménez et al., 2010). Treatment of mice with 
mitraphylline results in changes in cytokine modulation corresponding to a decrease in 
inflammatory signals (Rojas-Duran et al., 2012).  
In the current research, HPLC analysis was performed on the U. tomentosa 
extracts to characterize the potential bioactive components. A high level of alkaloids 
was observed in ethanol extract, while a much lower level of the alkaloids was 
detected in PBS extract. This indicates that there is a similarity with other studies, 
showing that the U. tomentosa extracts contain a significant amount of alkaloids. Many 
of the peaks that were identified were shown to correspond to the known standard 
alkaloid components of U. tomentosa, including uncarine D, mitraphylline, uncarine C, 
isomitraphyline, rhynophyline, and uncarine E. The observation that our ethanol 
extracts had much stronger anti-proliferative effects than did the PBS extracts supports 
the idea that the alkaloid fraction contributes to the biological activity of U. tomentosa.  
The synergistic action of alkaloids in combination with non-polar compounds is 
proposed to lead to the antitumor activities of U. tomentosa extracts (Pilarski et al., 
2010). The compounds, which appear to be important, include uncarine F, 
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isomitraphylline, mitraphylline, isopteropodine, and pteropodine. These compounds 
also have been shown to display anti-apoptotic activities against lymphoblastic 
leukemia cells (Bors et al., 2012). Furthermore, studies have proved that extracts of U. 
tomentosa have potent antioxidant properties. It has been shown that extracts of the 
plant were able to scavenge oxygen-derived radicals like hydroxyl radicals and 
superoxide anions, as well as avert lipid membrane oxidation (Goncalves et al., 2005). 
Collectively, these data provide compelling evidence that the U. tomentosa extract 
contains strong anticancer bioactive compounds that require further isolation and 
additional characterization. 
 
2.4.2 Anti-proliferation activity of U.  tomentosa extracts 
The changes in proliferation rates for B16-BL6 cells and 4T1 cells treated with 
various doses of U. tomentosa extracts were determined using the MTT assay. The 
MTT assay converts yellow tetrazolium MTT to purple formazan crystals based on the 
activity of NAD(P)H-dependent cellular oxidoreductase enzymes. Therefore, the 
amount of formazan that formed reflected the number of metabolically active viable 
cells present in the culture (van Meerloo et al., 2011). In the present research, the 
growth of 4T1 cell cultures was significantly inhibited following treatment with U. 
tomentosa extracted with 70% ethanol at concentrations of 40 and 200 µg/ml (the 
medium and high doses). Similarly, the growth of B16-BL6 cell cultures was greatly 
inhibited following treatment with 40 and 200 mg/ml of the ethanol extracts of U. 
tomentosa.  In both cell lines, there was no significant difference in cell number until 
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at least day 2 or 3 of treatment. This supports the idea that treatment with the U. 
tomentosa extracts does not simply induce necrosis in the cell cultures but rather 
induces a process that requires a few days (or a few cell divisions) for the differences 
to be detected. 
Treatment of 4T1 and B16-BL6 cells with U. tomentosa extracted with PBS at 
200 µg/ml (high dose) was able to partially inhibit cell growth although not to the 
same extent as treatment with the ethanol extract. Treatment of B16-BL6 cells with 
200 µg/ml of the PBS extract of U. tomentosa almost completely inhibited cell growth 
while similar treatment of the 4T1 cells only blocked cell growth by approximately 
50%. Treatment of both B16-BL6 and 4T1 cells with 40 µg/ml of the PBS extract of 
U. tomentosa did not significantly inhibit cell growth. The findings from this research 
indicated that the B16-BL6 cell line was more sensitive to U. tomentosa treatment, 
while the 4T1 cell line was more resistant. In addition, treatment with the ethanol 
extract of U. tomentosa was more effective as an anti-cancer agent than the PBS 
extract of U. tomentosa in vitro.  
This result is similar to other studies where U. tomentosa extracted with water 
(C-Med-100) was tested against two human leukemic cell lines (K562 and HL60) and 
one human EBV-transformed B lymphoma cell line (Raji) using a clonogenic assay. 
The results showed that the treatment significantly inhibited HL60 and Raji cells, but 
K562 was more resistant to the U. tomentosa treatment (Sheng et al., 1998). Other 
results from our laboratory (Alfarteesh MSc thesis 2014; Aljehani MSc thesis 2015) 
have also shown that treatment of a number of human cancer and non-malignant cell 
lines, including MCF-7, MDA-MBA-231, HBL-100 breast cells, HeLa cervical cancer 
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cells, HEK293 embryonic kidney cells, and HSG epithelial cells with U. tomentosa 
extracts can significantly inhibit cell growth. Further, these data all showed that the 
ethanol extract of U. tomentosa had a stronger inhibitory effect on cell proliferation 
than the PBS extract. These results are consistent with our finding that U. tomentosa 
has the ability to inhibit the proliferation of both the B16-BL6 and 4T1 murine cancer 
cell lines. 
The effect of various ethanol fractions derived from the ethanol extract of U. 
tomentosa was tested for antiproliferative effects on B16-BL6 and 4T1 cells. These 
fractions were shown to have different levels of the alkaloid components using HPLC. 
The 40% ethanol fraction was shown to have the highest amount of the total alkaloids, 
which included uncarine D, mitraphylline, uncarine C, isomitraphyline, rhynophyline, 
and uncarine E. The 20% fraction had lower levels of total alkaloids but had a higher 
relative percentage of rhynophyline, and uncarine E. The 60% fraction had a higher 
relative percentage of uncarine D and mitraphylline. Both the water and 80% ethanol 
fractions had very low levels of total alkaloids. Treatment of both B16-BL6 and 4T1 cells 
with the 60% ethanol fraction promoted a significant inhibition of cell growth. However, 
treatment with the 80% ethanol fraction had the most potent effect on 4T1 cell growth but 
still had a strong effect on B16-BL6 cells. Treatment with the 40% ethanol fraction had a 
relatively small effect on cell proliferation. This suggests that the alkaloids present in U. 
tomentosa are not sufficient to promote the changes in cell proliferation; the alkaloids 
may be required in combination with other components that were not detected by the 
HPLC analysis. Further, B16-BL6 and 4T1 cells did not show identical responses to the 
different U. tomentosa fractions suggesting the potential for cell-specific differences in 
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response to components of U. tomentosa. However, it should be noted that the purified, 
lyophilized fractions had been stored for several months between testing on the B16-BL6 
and 4T1 cells and some potentially bioactive components might have been degraded 
during that period which could explain the different results. 
 
2.4.3 Anti-proliferation activity of U. tomentosa extracts using Ki-67 
protein expression 
The expression of the Ki-67 antigen is linked to tumour cell proliferation. Ki-
67 staining is commonly used in pathology labs and cancer diagnosis as a proliferation 
marker (Li et al., 2015). In this research, Ki-67 staining was performed to test for the 
effect of treatment with U. tomentosa on the proliferation of B16-BL6 and 4T1 cells. 
Both B16-BL6 and 4T1 cells treated with the ethanol extract of U. tomentosa showed a 
dose-dependent reduction in Ki-67 staining. Cells treated with the low dose of U. 
tomentosa (4 µg/ml) for 2 days showed a small reduction in Ki-67 staining while cells 
treated with the high dose of the ethanol extract of U. tomentosa (200 µg/ml) showed a 
high reduction of Ki-67 staining. Treatment of both B16-BL6 and 4T1 cells with the 
PBS extract of U. tomentosa showed a lower reduction of Ki-67 staining compared to 
the ethanol extract. Treatment with the low dose of the PBS extract of U. tomentosa 
for 2 days did not significantly inhibit Ki-67 staining while treatment with the high 
dose for 2 days was able to partially inhibit Ki-67 staining. This confirms the relative 
effectiveness of the ethanol extract of U. tomentosa against cancer cells. 
Similarly, Zhu et al. (2014) showed that Artemisinin, a component isolated 
from a Chinese medicinal plant, has strong anticancer activities against several types 
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of human tumours. Researchers examined the effect of treating neuroblastoma cells 
with either DMSO (control) or 300 μM artemisinin over a period of 72 hours. Then, 
cells were stained with an antibody against Ki-67 and the percentage of Ki-67-positive 
cells was measured using a microscope. The results have shown that treatment with the 
plant extract significantly inhibited the proliferation of neuroblastoma cells as 
measured by a decrease in Ki-67 staining (Zhu et al., 2014). Collectively, the results 
from Zhu and colleagues (2014) support the idea that extracts from medical plants are 
effectively able to inhibit Ki-67 staining in different cancer cell lines. 
 
2.4.4 DNA fragmentation caused by treatment with the U. tomentosa 
extracts 
A TUNEL assay was used to detect DNA fragmentation that is considered an 
essential feature of apoptotic cell death. The TUNEL assay depends on the enzyme 
terminal deoxynucleotidyl transferase (TdT), which adds labelled deoxynucleotides to 
the 3’-hydroxyl terminus of the free ends of DNA that are significantly increased when 
the DNA is fragmented by caspase or nuclease activity (Nagata, 2000). In the present 
research, the TUNEL technique was performed to investigate whether treatment with 
the U. tomentosa extract induces apoptosis in the B16-BL6 and 4T1 cell lines. 
Treatment of both B16-BL6 and 4T1 cells with the high dose of the ethanol extract of 
U. tomentosa (200 µg/ml) showed the presence of apoptotic cells after 24 h which 
were significantly increased at longer treatment times. Treatment of cells with both the 
low (4 mg/ml) and medium (40 mg/ml) doses of the ethanol extract was shown to 
promote apoptosis in some cells at longer treatment times.  
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On the other hand, treatment with high doses of the PBS extract of U. 
tomentosa for 2 or 3 days showed a lower level of cell death in both B16-BL6 and 4T1 
cell lines when compared to the ethanol extract. However, no apoptotic cells were 
detected when the cells were treated with the low doses of the PBS extract. This 
indicates that the treatment with the ethanol extract was more effective at inducing 
apoptosis than the treatment with the PBS extract. 
Similar studies from our laboratory have examined the effectiveness of U. 
tomentosa on the growth and survival of B16-BL6 cells. Results indicated that U. 
tomentosa extracted with ethanol was able to increase DNA fragmentation in the B16-
BL6 cells using the TUNEL assay (Alfarteesh, 2014). An in vitro study has previously 
used the U. tomentosa as a treatment against MCF 7 cancer cells in vitro. The study 
showed that treatment with U. tomentosa extracted with ethanol significantly increased 
the apoptotic cells in MCF 7 cells. However, treatment with U. tomentosa extracted 
with PBS demonstrated a lower effect (Aljehani, 2015). These results are consistent 
with our finding that U. tomentosa extracted with ethanol clearly increased DNA 
fragmentation in both cell lines, especially when treated at the highest dose. It is also 
interesting that in all of these studies, treatment of the cells with U. tomentosa required 
at least 1 or 2 days before there were a significant number of apoptotic cells. This is 
consistent with the observation that the differences in cell culture growth, as measured 
by MTT assays, required at least 3 days to be significant. This further suggests that the 
mechanism by which treatment with U. tomentosa extracts inhibits cell growth is by 
the induction of apoptosis. 
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2.4.5 Apoptosis induction by U. tomentosa extract detected using flow 
cytometry 
In order to confirm that U. tomentosa extract induces apoptosis in 4T1 cancer 
cells, flow cytometry was performed using propidium iodide staining. In this research, 
4T1 cells were treated with various doses of U. tomentosa extracts over two different 
time periods (24 hours and 48 hours). At the highest dose (200 µg/ml), the results 
showed that the U. tomentosa extracted with ethanol induced a significant 
accumulation of cells in the sub-G1 peak after 48 hours, which increased to over 74% 
of apoptotic cells. However, the treatment with U. tomentosa extracted with PBS was 
less active and recorded around 13% of the apoptotic cells after 48 hours. Treatment of 
cells with the low dose of U. tomentosa extracts did not significantly increase the 
percentage of apoptotic cells in the pre-G1 peak compared to controls. It is interesting 
to note that treatment with U. tomentosa extracts did not affect the cell cycle 
distribution of cells between the G1, S, and G2/M phases of the cell cycle. This 
suggests that treatment with U. tomentosa extracts did not inhibit cell culture growth 
by inhibiting cell proliferation, but rather promoted its effects primarily by inducing 
apoptosis. 
Similar data was obtained through other studies that used the U. tomentosa 
extract against cancer cells in vitro. Rinner et al. (2009) showed that the alkaloids 
isopterpodine and pteropodine isolated from U. tomentosa had a remarkable pro-
apoptotic effect on Medullary thyroid carcinoma (MTC). In this study, flow cytometry 
was used to examine the effect of the plant extracts on MTC cell cycle distribution. 
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Researchers concluded that the number of cells in the sub-G1 peak was increased 
following treatment with the U. tomentosa extract for 48 h (Rinner et al., 2009).  
In another study from our laboratory, the effect of U. tomentosa extract on B16-
BL6 cells was investigated using flow cytometry. Briefly, cells were treated with 
multiple doses of U. tomentosa extracted with ethanol or PBS and then incubated with 
PI staining solution and analyzed using a Beckman Coulter LS600 flow cytometer. The 
study found that treatment with U. tomentosa extracted with ethanol caused a great 
increase in sub-G1 cells that increased to over 70% of the cells after 3 days of 
treatment (Alfarteesh, 2014). Taken together, these results are strongly consistent with 
our finding that treatment with U. tomentosa extract significantly induced apoptosis in 
4T1 cancer cells. 
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Chapter 3. Uncaria tomentosa extracts were examined in vivo to 
measure the growth and survival of B16-BL6 cancer cells 
 
3.1 Introduction 
U. tomentosa has a long history of use in traditional medicine for over 2000 years 
by indigenous cultures in South America (Keplinger et al., 1999). Several studies have 
shown that this plant has immunostimulant, anti-inflammatory, anti-oxidant, and anti-
cancer properties (Heitzman et al., 2005; Zhang et al., 2015). However, there is relatively 
little in vivo data to show how U. tomentosa might inhibit tumour growth. Various studies 
have shown U. tomentosa can affect both the response of the immune system and the 
growth of the cancer cells themselves. For example, the antitumor and antioxidant 
activities of U. tomentosa hydroalcoholic extract were examined in vivo. Researchers 
found that animals treated with U. tomentosa extracts showed a reduction in the tumor 
growth of Walker-256 cancer cells and a reduction in the activity of aspartate 
aminotransferase (AST). In addition, tumoural activity of catalase (CAT) was reduced in 
tumour tissue, while in the liver CAT activity was increased. In the liver and in the 
tumour, SOD activity was significantly decreased (Dreifuss et al., 2010).  
Another study showed that a pentacyclic oxindole alkaloid extract from U. 
tomentosa bark had the ability to treat T-helper 1 immune-mediated disorders without 
showing immunotoxicity or cytotoxic on murine splenocytes (Domingues et al., 2011). 
Since tumour growth is usually considered to be a balance between immune system 
escape and tumour cell growth, the experiments were designed to show the impact of U. 
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tomentosa on immune responses against the tumour and the effects of U. tomentosa 
directly on the tumour cells.  
In this study, an isogenic tumour transplantation model was performed to 
determine the anti-cancer activities of U. tomentosa extracts in C57BL/6 mice. This 
animal model was selected because the B16-BL6 cells are syngeneic with the C57BL/6 
mice allowing experiments to be performed in an immuno-competent host. Tumours were 
formed by subcutaneous injection of B16-BL6 cancer cell in the right flank of mice. Two 
types of injections were used for treatment with U. tomentosa extracts, including 
intraperitoneal (IP) and intratumour (IT). Subsequently, animals were sacrificed and 
tumour tissues were collected in order to measure tumour size and weight.  
Histochemical analysis of the B16-BL6 tumours was also performed to examine 
the anti-cancer activities of U. tomentosa extracts on cell growth (Ki67 proliferation 
marker), cell death (TUNEL staining), and angiogenesis (Factor VIII). As well, 
alterations in immune cell infiltration caused by U. tomentosa extracts were evaluated 
using immunohistochemistry for a number of immune cell markers including CD3, CD4, 
CD8, ICAM - 1, E - selectin, PECAM -1, Integrin αIIb, CD19, and CD45. Together, 
these animal experiments were performed in order to evaluate the suitable composition, 
significant medicinal activity, as well as the safety and risk of the plant extracts. 
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3.2 Materials and Methods 
3.2.1 Uncaria tomentosa extracts  
Uncaria tomentosa was obtained from Rosario Rojas (Lima, Peru) as a dried 
powder prepared from the bark or was purchased as a natural product supplement (Cat's 
Claw extract, Now Foods, Bloomington, IL. code 84618). The dried plant product was 
extracted with either PBS, pH7.4, or 70% ethanol and the soluble fraction used in the 
current research. For the preparation of the ethanolic extracts, 20 g of U. tomentosa 
powder was suspended in 200 ml 70% ethanol and heated to a slow boil with refluxing 
for 1 hour. For the preparation of PBS extracts, 20 g of U. tomentosa powder was 
suspended in 180 ml water and 20 ml 10xPBS buffer and heated to a slow boil with 
refluxing for 1 hour. The mixture was allowed to cool and the bark debris was removed 
by centrifugation of the suspension at 2000 x g for 10 min. The supernatant was removed 
and filtered using a 0.22 μm syringe filter and then the extract was stored in aliquots at -
80 °C. For both the animal experiments and the chemical fractionation experiments, the 
U. tomentosa extract supernatants were frozen and dried by lyophilization into a powder. 
The powder was weighed and resuspended in water immediately prior to use for the 
experiments. 
 
3.2.2 Animal Experiments  
The B16-BL6 melanoma/C57bl/6 isogenic tumour transplantation model was 
performed to determine the anticancer activities of U. tomentosa extracts in mice. A total 
of 50 syngeneic male C57BL/6 mice (8 weeks old) were used for two experiments 
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(Charles River, Pointe-Claire, QB, Canada). In particular, 25 male mice were used for 
each experiment (experiment 1 and experiment 2) over a period of 21-24 days or when 
the tumor size reached the endpoint. Animals were housed in disposable plastic shoebox 
cages with 5 individuals per cage and acclimated in their cages over a period of 3 weeks. 
Each cage had a high density and actively vented system with a complete cage 
sanitization weekly during the experiment period. In addition, the room was maintained 
on a 12:12-h light: dark cycle; average room temperature was between 20°C and 21°C. 
The mice received a standard pellet diet and water providing ad libitum. 
Tumours were induced by injection of B16-BL6 cancer cells in the right flank of 
mice subcutaneously. The mice were injected with 2 x 105 cells, suspended in 100 µl of 
PBS. All of the animals were injected with tumour cells and were then randomly assigned 
into one of five equal groups (5 individuals in each group). The first group was the 
vehicle control (mice were received just PBS to determine whether the vehicle alone 
causes any effects), the second group consisted of mice that were treated with 100 μl of 
200 μg/ml ethanol extract of U. tomentosa using intraperitoneal injection, the third group 
of mice were treated with 100 μl of 200 μg/ml ethanol extract of U. tomentosa using 
intratumour injection, the fourth group of mice were treated with 100 μl of 200 μg/ml 
PBS extract of U. tomentosa using intraperitoneal injection, and the fifth group consisted 
of mice that had been treated with 100 μl of 200 μg/ml PBS extract of U. tomentosa using 
intratumour injection. For animals receiving intraperitoneal injections, the first injection 
was performed 3 days after injection of the tumour cells and then performed two times 
per week for 2 weeks (4 injections in total). For animals receiving intratumour injections, 
the animals in experiment 1 received injections only after the tumours were palpable (day 
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11) while the animals in experiment 2 received injections beginning 3 days after injection 
of the tumour cells. Therefore, the animals in experiment 1 received two intratumour 
injections while the animals in experiment 2 received 4 intratumour injections.  
Physiological and behavioral data were assessed daily during the experiment, 
including general appearance, foraging or feeding, muscle tone, body tone, sleeping, and 
aggressive or defensive behavior. Also, animals were monitored for any signs of 
morbidity or mortality and regular weight measurements were recorded every two days 
by individually weighing each animal. At experimental endpoints, mice were euthanized 
via CO2 exposure, in compliance with the Canadian Council for Animal Care 
recommendations.  
Post treatment, all tumours were fully collected from the mice and their diameter 
and weight were measured. For additional analysis, the tumours were fixed in EFA (720 
ml ethanol (100%), 180 ml distilled water, 50 ml glacial acetic acid and 50 ml 
formaldehyde). Tumour weight and size data were tested by two-way analysis of variance 
(ANOVA) and post-hoc Tukey HSD tests (SPSS for windows). Differences were 
considered significant at P values of 0.05 or less. All animal experiments were approved 
by the Laurentian University Animal Care Committee, protocol 2013-12-01, in 
accordance with guidelines established by the Canadian Council for Animal Care. 
 
3.2.3 Histochemical analysis of tissue sections 
Histochemical analysis of the isolated tumours was performed in the current 
research. Several immune, cell growth, and cell death markers were used to examine the 
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impact of treatment on B16-BL6 tumours. Specifically, 29 samples were sent to 
University of Ottawa, Department of Pathology and Laboratory Medicine, Histology 
Core Facility (HCF) for processing, embedding, and sectioning. These 29 samples 
included 10 tumours treated with just PBS and used as vehicle control, 10 tumours treated 
with ethanol extract of U. tomentosa using intraperitoneal (IP) injection, and 9 tumours 
treated with PBS extract of U. tomentosa using intraperitoneal (IP) injection.   
Immunohistochemistry staining was performed in the lab for Ki-67 and factor 
VIII staining using ABC immunohistochemistry kits (Santa Cruz Biotech). The slides 
were deparaffinized by submerging in the first container of xylene for 2 min, the second 
container of xylene for 2 min, the third container of xylene for 2 min, and then rehydrated 
using an ethanol series of 100% ethanol for 5 min, 95% ethanol for 5 min, 70% ethanol 
for 3 min, 40% ethanol for 3 min, 20% ethanol for 3 min, and distilled water for 1 min. 
Then, slides were submerged in sodium citrate buffer (10 nM sodium citrate, 0.05% 
Tween 20, pH 6.0) at 95°C for 30 min for antigen retrieval. Blocking serum (Santa Cruz 
Biotech) was incubated with the slides for 1 hour and then the slides were incubated with 
anti-Ki-67 (Santa Cruz Biotech) or anti-Factor VIII (Santa Cruz Biotech) antibodies at a 
titre of 1:100 in binding buffer in a humidified chamber overnight. The following day, the 
slides of tumours were washed 3 times using PBS, pH 7.4, for 5 min each. Biotinylated 
secondary antibody was incubated with the sections for 30 min at room temperature. 
Slides were washed 3 times with PBS for 5 min. The AB enzyme reagent was used to 
treat the sections for 30 min and then slides were washed 3 times using PBS. Peroxidase 
Substrate was added for 20 min and then samples were washed with distilled water for 5 
min. Samples were counterstained by incubating in Haematoxyline for 6 min. Slides were 
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rinsed with lukewarm running water and then 1% acid alcohol solution (70% ethanol and 
1% HCl) was used (3 dips). The samples were rinsed with tap water and then with 
saturated lithium carbonate (approximately 0.2 M lithium carbonate) for 3 dips to develop 
the haematoxyline stain. The slides were then rinsed with tap water for 10 min. The 
stained sections were then dehydrated in an ethanol series of 95% ethanol, 95% ethanol, 
100% ethanol, 100% ethanol, and then placed in the first container of xylene for 2 min, 
the second container of xylene for 2 min, and the third container of xylene for 2 min. 
Coverslips were mounted on glass slides in Permount and then analyzed using an 
Olympus IX3 microscope. 
For immune markers, the slides were deparaffinized and hydrated by submerging 
in the first container of xylene for 2 min, the second container of xylene for 2 min, the 
third container of xylene for 2 min, and then in the ethanol series composed of 100% 
ethanol for 5 min, 95% ethanol for 5 min, 70% ethanol for 3 min, 40% ethanol for 3 min, 
20% ethanol for 3 min, and distilled water for 1 min. The slides were also submerged in 
sodium citrate buffer (10 nM sodium citrate, 0.05% Tween 20, pH 6.0) at 95°C for 30 
min for antigen retrieval. Then, the slides were incubated with the blocking serum for 1 
hour. The slides were then incubated with a combination of 3 fluorescently-tagged 
primary antibodies labeled with Alexa-488, Alexa-546, or Alexa-633. In the first section 
on the slide, three control antibodies were combined (normal rat IgG2a-Alexa-633, 
normal mouse IgG2b-Alexa-546, normal mouse IgG1-Alexa-488) in a total of 90 µl (30 
µl each) suspended in 1.5 ml of block buffer. Each slide section was stained by 
incubation with 50 μl of this solution overnight at room temperature in a humidified 
chamber. In the second section of the slide, cells were stained with antibodies that 
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recognize T cells. Anti-CD3-Alexa-546, anti-CD4-Alexa-488 and anti-CD8-Alexa-633  
antibodies were combined in a total of 90 µl (30 µl each) and suspended in 1.5 ml of 
block buffer. The sample was stained with 50 μl of this solution overnight at room 
temperature in a humidified chamber. In a third tissue section, the slides were incubated 
with antibodies against the leukocyte markers, anti-Integrin αIIB-Alexa-633, anti-CD19 
and anti-CD45 were combined in a total of 90 µl (30 µl each) and suspended in 1.5 ml of 
block buffer. The sample was stained with 50 μl of this solution overnight at room 
temperature. 
Markers corresponding to endothelial cells and to activated endothelial cells were 
also used. In the fourth tissue section, anti-ICAM-1-Alexa-633, anti-E-selectin-Alexa-
546, and anti-PECAM-1-Alexa-488 were combined in a total of 90 µl (30 µl each) and 
suspended in 1.5 ml of block buffer. The sample was stained with 50 μl of this solution 
overnight at room temperature. All slides were analyzed using an Olympus IX3 
fluorescence microscope through different channels (green, red, and far red) with control 
experiments showing minimal overlap between the channels.  
 
3.2.4 TUNEL staining of histochemical sections 
For TUNEL staining of histochemical sections, the slides were deparaffinized and 
hydrated by submerging in the first container of xylene for 2 min, the second container of 
xylene for 2 min, the third container of xylene for 2 min, 100% ethanol for 5 min, 95% 
ethanol for 5 min, 70% ethanol for 3 min, 40% ethanol for 3 min, 20% ethanol for 3 min, 
and distilled water for 1 min. Following that, slides were submerged in 10 nM sodium 
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citrate buffer and treated in the microwave oven for 1 min. Samples were washed three 
times with PBS, pH 7.4. The slides were then immersed in a block buffer containing 10 
ml of 100 mM Tris-HCl, pH 7.5, 20% FBS, and 3% BSA for 30 minutes. Samples were 
washed twice with PBS, pH 7.4. Each section was stained by incubation with 50 µl of 
TUNEL reaction mixture (Roche) for 60 min at 37°C in a humidified chamber in the 
dark. Images were captured using an Olympus IX3 fluorescence microscope for analysis. 
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3.3 Results 
3.3.1 Examining the anticancer activities and protective effects of U. 
tomentosa extracts on male C57BL/6 mice by measuring body weight, 
tumour weight, and tumour size 
A total of 50 male C57BL/6 mice were used for two experiments. Animals were 
divided randomly into five equal groups (5 mice in each group) in each experiment. 
Tumours were initiated by injection of approximately 105 B16-BL6 cells in the right 
flank of mice subcutaneously. For these experiments, U. tomentosa was extracted into 
70% ethanol or PBS, pH 7.4, and the supernatant lyophilized to produce a powder. This 
powder was then resuspended in PBS, pH 7.4 for injection to avoid injecting ethanol into 
the mice. These U. tomentosa extracts resuspended in PBS, pH 7.4, were injected into 
mice intraperitoneally or directly into the tumor. In the first experiment, the mice 
received a total of 4 intraperitoneal injections of the extracts; the first injection was 3 
days after injection of the tumour cells and then injections were made twice a week. 
However, in experiment 1 the mice received only 2 injections into the tumour starting 
only during week 2 (Tables 3.1 – 3.3). This was done to allow time for palpable tumours 
to form before injections. In the second experiment, all of the treated groups, both 
intraperitoneal injection and injection into the tumour were performed 4 times over a 
period of 14 days. The injections into the tumour for week two, before there was a 
palpable tumour, were made into the approximate site of tumour injection (Tables 3.4 – 
3.6). Animal weight was measured and the tumour size was estimated using calipers 
every second day. The animals were sacrificed on around day 18 and all tumours were 
excised and collected. The weights of each mouse and the weight and average diameter of 
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each tumour were recorded. The tumours were then fixed by incubation in EFA (ethanol 
formalin, acetic acid fixative) for histochemical analysis. 
For statistical analysis, two-way analysis of variance was applied by combining 
the results for both experiments (Tables 3.7 – 3.9). In terms of body weight, no 
significant differences between the five groups were found (Figure 3.28). Also, no 
significant effects of experiment or group by experiment interaction on body weight were 
recorded. Significant effects of group (P < 0.001) on tumour weight were found in mice 
treated with U. tomentosa extracted with ethanol or PBS (Table 3.8, Figure 3.29). 
Furthermore, there was a significant group by experiment interaction (P < 0.05). 
However, no significant effects of experiment on tumour weight were found. Tukey HSD 
tests were used for additional analysis. In these tests, significant differences between each 
of the four treated groups and the vehicle control (P < 0.05) were recorded. However, no 
significant differences between the four treated groups were shown. 
Additionally, tumour size was less affected than tumour weight in mice treated 
with U. tomentosa extracted with ethanol or PBS. In particular, significant effects of 
group (P < 0.01) on tumour size were found using two-way ANOVA (Table 3.9, Figure 
3.30), but no significant effects of experiment or group by experiment interaction on 
tumour size were shown. In Tukey HSD tests, results indicated no significant differences 
among the four treated groups. However, the vehicle control was significantly different 
from each of the four groups (P < 0.05).  
A strong relationship between tumour size and tumour weight (P < 0.001) was 
recorded (Table 3.10, Figure 3.31). The tumour size is strongly correlated to the tumour 
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weight (r = 0.85, P < 0.001). Furthermore, results indicated that all treated groups 
decreased tumour weight and tumour size in the same manner. Specifically, no significant 
major effects or interactions between the levels of treatment (injection type: IP vs IT and 
extract type: ETOH vs PBS) were found using two-way ANOVA. 
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Significantly different from the control (**P < 0.01 and ***P < 0.001). 
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Figure 3.28 Body weight was evaluated following the use of U. tomentosa 
treatment 
In this research, all animals were injected with B16-BL6 tumour cells and then 
received intraperitoneal (IP) injections or injections directly into the tumour (IT) with U. 
tomentosa extracted with 70% ethanol (ETOH) or PBS, pH 7.4, (PBS) in accordance with 
guidelines provided by the Animal Care Committee at Laurentian University. At the 
endpoint of the experiment, the mice were euthanized by CO2 asphyxiation and tumours 
were surgically removed to determine the tumour diameters, weights, and body weights. 
The average of the total of body weight is shown in grams for the animals in each of the 
five groups (+ standard error, N= 9-10). Results demonstrated that there were no 
significant differences in total body weight between the five groups. 
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Figure 3.29 Tumour weight was evaluated following the use of U. 
tomentosa treatment 
In this research, all animals were injected with B16-BL6 tumour cells and then 
received intraperitoneal (IP) injections or injections directly into the tumour (IT) with U. 
tomentosa extracted with 70% ethanol (ETOH) or PBS, pH 7.4, (PBS) in accordance with 
guidelines provided by the Animal Care Committee at Laurentian University. At the 
endpoint of the experiment, the mice were euthanized by CO2 asphyxiation and tumours 
were surgically removed to determine the tumour diameters, weights, and body weights. 
The average tumour weight in grams for each of the five treatment groups (+ standard 
error, N= 9-10) is shown. Results demonstrated that there were significant differences 
between each of the four treated groups compared to the control. 
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Figure 3.30 Tumour size was evaluated following the use of U. tomentosa 
treatment 
In this research, all animals were injected with B16-BL6 tumour cells and then 
received intraperitoneal (IP) injections or injections directly into the tumour (IT) with U. 
tomentosa extracted with 70% ethanol (ETOH) or PBS, pH 7.4, (PBS) in accordance with 
guidelines provided by the Animal Care Committee at Laurentian University. At the 
endpoint of the experiment, the mice were euthanized by CO2 asphyxiation and tumours 
were surgically removed to determine the tumour diameters, weights, and body weights. 
The average tumour diameter in cm for the animals in each of the five groups (+standard 
error, N= 9-10) is shown. Results demonstrated that there were significant differences 
between each of the four treated groups compared to the control. 
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Figure 3.31 The correlation between tumour weight and tumour size in 
C57BL/6 mice 
The in vivo study showed that when the tumour size increased, the tumour 
diameter also increased. This means there was a direct positive proportional relationship 
between tumour weight and tumour size, as indicated in the Figure 3.30.  
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3.3.2 Histochemical analysis was performed for B16-BL6 tumours 
The B16-BL6 tumours isolated from the mice were subjected to histochemical 
analysis to measure the impact of treatment with U. tomentosa on immune, cell growth, 
and cell death markers. The tumours were resected and fixed by incubation in EFA 
fixative and then subjected to processing, embedding, and sectioning in collaboration 
with the University of Ottawa Core Histochemistry facility. Twenty-nine tumour samples 
including ten tumours taken from mice treated with just PBS and used as vehicle control, 
ten tumours from mice treated with the ethanol extract of U. tomentosa using 
intraperitoneal injection, and nine tumours from mice treated with the PBS, pH 7.4, 
extract of U. tomentosa using intraperitoneal injection. Different staining protocols were 
applied to the tissues depending on the marker used for analysis as described in detail in 
the materials and methods. The level of staining was assessed using an ordinal intensity 
staining scale where a value of 0 is assigned to sections that showed no staining and value 
of 5 was assigned to a section that stained very strongly. For each marker, the cumulative 
staining intensity was determined for 3 random fields taken from the center of the tumour 
and 5 random fields from the periphery of the tumour for each mouse. The staining 
intensity value for each mouse was then averaged for all mice in the same group and used 
for analysis. One-way ANOVA was used for statistical analysis and also LSD tests were 
performed for further analysis.  
The level of staining with the Ki-67 antibody was determined in each of the 
tumour sections and scored for the average for each mouse (Figure 3.32). The Ki-67 
antigen has been shown to be expressed in the nuclei of cells that are actively 
proliferating. Examination of the sections at high magnification confirmed that the 
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positive staining was associated with the nucleus in many of the cells. Staining with the 
Ki-67 antibody was detected in a number of different cells in the majority of the sections. 
The staining intensity for Ki-67 in tumours isolated from mice that had been treated with 
only PBS, pH, showed a significantly higher staining score (25.2+1.4, SEM) than did 
tumours from mice treated with the ethanol extract of U. tomentosa (17.1+1.2) or the 
PBS extract of U. tomentosa (17.1+1.6) (Table 3.11, Figure 3.33). There was no 
difference in Ki-67 staining intensity between mice treated with the ethanol extract 
compared to the PBS extract of U. tomentosa. 
Staining for factor VIII was conducted as a marker of endothelial cells in the 
tumour sections as a marker of angiogenesis. Factor VIII staining was frequently 
associated with the presence of vessels in the tumour cross-section but in some sections 
staining was more diffuse in the tissue, which may indicate weakly organized vascular 
beds within the growing tumour. The average staining intensity for the factor VIII was 
greater in the tumours from mice treated with only PBS, pH 7.4 (24.3+1.3, SEM) 
compared to tumours from mice treated with the ethanol (17.4+1.6) or PBS (18.2+2.0) 
extract of U. tomentosa (Table 3.12, Figure 3.34).  
The level of the TUNEL staining reaction was examined as a measure of cellular 
apoptosis within the tumour tissue. The TUNEL reaction measures the amount of free 
DNA ends as an indicator of DNA fragmentation during apoptosis. Examination of the 
sections at high magnification indicated that positive staining was consistent with 
localization in the nucleus. The average staining intensity for TUNEL positive cells 
showed that the level of staining was lowest for the tumours from animals injected with 
only PBS, pH7.4, however, this was not significantly different from the level of staining 
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in the U. tomentosa extracted with ethanol or PBS (Table 3.13, Figure 3.35). It is 
interesting to note that the variability in TUNEL staining (as indicated by the standard 
deviation in scores) was significantly greater for the U. tomentosa-treated groups 
compared to the control group. 
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Figure 3.32 The presence of Ki-67-positive cells was detected in 
histochemical sections from mice treated with U. tomentosa extracts 
Twenty-nine tumours were used for histochemical analysis. Ki-67-staining was 
performed in order to measure the growth fraction of B16-BL6 tumours in vivo. The 
relative intensity of proliferating neoplastic cells was determined directly by light 
microscopy. The intensity of Ki-67-positive staining was determined in 8 random fields 
per slide: scores varied between fields based on the relative number of positive cells. Six 
scores were given to the photos: a score of 5 was given to a section with a high level of   
Ki-67-positive cells, and a score of 1 was assigned to a section with a low level of Ki-67-
positive cells while a section that did not have Ki-67-positive cells was scored as 0. The 
figure shows a typical microscopic filed corresponding to each of the assigned scores 
from 0 – 5.  
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Figure 3.33 The relative level of Ki-67-positive cells was decreased in 
histochemical sections from mice treated with U. tomentosa extracts 
Twenty-nine tumours were used for histochemical analysis using Ki-67-staining 
to measure the growth fraction of B16-BL6 tumours in vivo. The relative intensity of 
proliferating neoplastic cells was determined directly by light microscopy for 8 random 
fields per slide. The level of staining was assigned a score ranging from 5, which 
corresponded to a large proportion of the tissue stained positive for Ki-67, to 0, where no 
staining was present in the section. The cumulative score was determined for each mouse 
and then the average was determined for all mice in the same treatment group. A. This 
figure shows representative images corresponding to the average staining intensity for Ki-
67 for each treatment group. B. The bar graph shows the relative staining intensity for 
each group. One-way ANOVA showed significant differences (P < 0.0001) between the 
three groups. Further analysis with LSD tests showed significant differences between 
tumours treated with U. tomentosa extracted with ethanol and control tumours (P < 
0.0001), as well as, tumours treated with U. tomentosa extracted with PBS and the 
control tumours (P < 0.0001). 
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Figure 3.34 The relative level of Factor VIII-positive cells was 
significantly decreased in histochemical sections from mice treated with 
U. tomentosa extracts 
Histochemical analysis using staining with an antibody against Factor VIII in the 
B16-BL6 tumours in vivo was performed and the relative intensity for each histochemical 
section was determined directly by light microscopy for 8 random fields per slide. The 
level of staining was assigned a score ranging from 5, which corresponded to a large 
proportion of the tissue stained positive for Factor VIII, to 0, where no staining was 
present in the section. The cumulative score was determined for each mouse and then the 
average was determined for all mice in the same treatment group. A. This figure shows 
representative images corresponding to the average staining intensity for Factor VIII for 
each treatment group. B. The bar graph shows the relative staining intensity for each 
group. One-way ANOVA showed significant differences (P < 0.05) between the three 
groups. Further analysis with LSD tests showed significant differences between tumours 
treated with U. tomentosa extracted with ethanol and control tumours (P < 0.01), as well 
as, tumours treated with U. tomentosa extracted with PBS and the control tumours (P < 
0.05).  
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Figure 3.35 The relative level of TUNEL-positive stained cells in 
histochemical sections from mice treated with U. tomentosa extracts was 
not significantly altered 
Histofluorescence analysis using a TUNEL stain to detect the free ends of DNA in 
the B16-BL6 tumours was performed and the relative intensity for each section was 
determined directly by fluorescence microscopy for 8 random fields per slide. The assay 
is based on the incorporation of a fluorescent nucleotide at free DNA ends and increased 
fluorescence intensity correlates with DNA fragmentation. The level of staining was 
assigned a score ranging from 5, which corresponded to a large proportion of the tissue 
stained positive for the TUNEL reaction, to 0, where no staining was present in the 
section. The cumulative score was determined for each mouse and then the average was 
determined for all mice in the same treatment group. A. This figure shows representative 
images corresponding to the average TUNEL staining intensity for each treatment group. 
B. The bar graph shows the relative staining intensity for each group. One-way ANOVA 
did not show significant differences between the three groups.  
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3.3.3 Immune cell infiltration in B16-Bl6 tumours was studied using 
several immune markers 
Since U. tomentosa has been shown to have an effect on immune cell function, 
the effect of U. tomentosa injections on immune infiltration into the B16-BL6 tumours 
was examined. Tumours were isolated and prepared for processing, embedding, and 
sectioning from animals treated with PBS, pH 7.4 (n = 10), or U. tomentosa extracted 
with either 70% ethanol (n = 10) or PBS (n = 9). The sections were stained for various 
immune cell markers to determine if the U. tomentosa extracts can affect and potentially 
enhance the immune response against cancer as measured by immune cell infiltration into 
the tumour. Different fields from the middle and periphery of the tumours were imaged 
using an Olympus IX3 fluorescence microscope to detect labeled cells. For each immune 
marker, the relative number of positive cells was determined for 8 randomly chosen fields 
for each tumour samples (n=29). The scores varied between fields using an ordinal scale 
based on the relative number of stained cells. The photographs from each field was given 
a score from 0 – 5: a score of 5 was given to a section with a high level of stained cells, 
and a score of 1 was assigned to a section with a low level of stained cells while a section 
that did not have stained cells was scored as 0 (examples shown in Figure 3.36).  
Sections were stained for the presence of T cells (CD3, CD4, and CD8 positive 
cells), activated endothelial cells (PECAM-1, E-selectin, and ICAM-1 positive cells), 
total leukocytes (CD45 marker positive), B cells (CD19 positive cells) and platelets 
(integrin αIIB positive cells). Each section was simultaneously stained with three 
different primary antibodies each labelled with a different fluorochrome (Alexa-488 
green, Alexa-546 red, Alexa-633 far red). This allowed for direct comparison of different 
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subsets of cell within each section. For example, the relative level of CD4 and CD8 T 
cells infiltrating the tumour could be directly compared. Preliminary results showed 
relatively little overlap in staining between the different fluorochromes and images show 
differences in cells labelled with the different antibodies. Staining with control, non-
specific IgG showed a relatively low level of staining of the sections since exposure 
durations required to capture images were much longer for the control sections compared 
to all of the antibody-specific tissues (Figure 3.37). Further, analysis of the level of 
staining for the control sections showed no significant differences between the tumours 
from animals treated with the different experimental conditions (Table 3.14 – 3.16). For 
statistical analysis, none of the immune markers had significant differences among the 
three groups using one-way ANOVA. 
The tissue sections were stained with antibodies against the T cell markers CD3, 
CD4, and CD8 (Figure 3.38). CD3 is a multimeric protein complex that complexes with 
the T-cell receptor (TCR) and the ζ-chain (zeta-chain) to activate T lymphocytes (Kuhns 
et al., 2006) and is a marker common to all T cells (including both CD4 and CD8 T 
cells). For CD3 staining, a red channel was used for analysis. This showed a significant 
level of T cell infiltration into the majority of the tumour sections, which was present 
throughout the tumour tissue. Results indicated that the relative intensity of the tissue 
sections stained with the anti-CD3 antibody was not significantly altered between the 
three treatment groups (Table 3.18). CD4 is the common marker to identify helper T 
cells, although it can be found at low concentration on macrophages, monocytes, and 
dendritic cells. CD4 is considered a biomarker particular for MHC class II-mediated 
antigen presentation and “helps” the T cell receptor (TCR) to communicate with antigen-
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presenting cells (Zhu et al., 2010). CD4 cells were also present at significant levels in all 
of the tissue sections indicating a high level of infiltration into the tumours. In this study, 
the relative intensity of CD4-positive cells, in the green channel, showed no significant 
differences (P > 0.05) between the three treatment groups using one-way ANOVA (Table 
3.17). The CD8 co-receptor is associated with the T cell receptor that recognizes antigen 
in coordination with the MHC class I system (O'Rourkea and Mescher, 1993). CD8 is the 
common marker for Cytotoxic T lymphocytes. The tissue sections also showed 
significant staining for CD8 positive cells indicating significant infiltration of CD8+ T 
cells into the tumour tissue. One-way ANOVA showed no significant differences (P > 
0.05) between the three treatment groups in the relative amount of CD8-positive cells 
measured in the far red panel (Table 3.19).  
PECAM -1 is a glycoprotein used as a marker for the presence of endothelial cells 
but is also expressed on the cell surfaces of monocytes, platelets, neutrophils, and 
subpopulation of T cells (Ganjei-Azar and Nadji, 2007). PECAM -1 staining was 
detected in the green channel (Figure 3.39) and was present at high levels in the tumour 
sections. In this research, the relative number of PECAM -1-positive cells showed no 
significant differences (P > 0.05) between the three groups using one-way ANOVA 
(Table 3.20). E-selectin is expressed on cytokine-stimulated endothelial cells and has a 
significant role in inflammation (Collins et al., 1991). E-selectin is a common marker of 
vascular inflammation and was present at significant levels in all of the tissue sections 
examined. Results indicated that the relative intensity of cells stained with E-selectin, in 
the red channel, was not greatly altered between the three groups (Table 3.21). The 
intercellular adhesion molecule-1 (ICAM-1) is an integral membrane protein of the 
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immunoglobulin superfamily. It plays an important role in immune responses and 
inflammation and is also a marker of vascular inflammation (Marlin and Rothlein, 1998). 
ICAM-1 was expressed in the majority of tissue sections. One-way ANOVA showed no 
significant differences (P > 0.05) between the three groups in the relative intensity of 
ICAM-1-positive cells (3.22).  
Histochemical sections were stained with antibodies that recognize CD45, CD19, 
and integrin αIIb (Figure 3.40), CD45 is a transmembrane glycoprotein that is expressed 
on nucleated cells of hematopoietic origin acting as a common leukocyte marker. It has a 
significant role for T- and B-lymphocyte activation (Altin and Sloan, 1997). In this study, 
high levels of CD45 staining were detected in all of the tissue sections supporting the idea 
that there was a significant level of immune cell infiltration into the tumours. The relative 
intensity of CD45-positive cell staining showed no significant differences (P > 0.05) 
between the three treatment groups using one-way ANOVA (Table 3.23). The human 
CD19 antigen is considered a transmembrane glycoprotein that expressed in all B lineage 
cells. It has a significant importance in human B cells by reducing the threshold for B cell 
receptor signaling pathways through its work in the CD19/CD21 complex. CD19 is also 
considered an important biomarker for B lymphocyte development because of its 
existence on all B cells (Scheuermann and Racila, 1995). The number of CD19+ cells 
indicated that there was significant infiltration of B cells into the B16-BL6 tumours. 
Results indicated that the percentage of cells stained with CD19 was not greatly altered 
between the three treatment groups (Table 3.24).  
Integrins are considered heterodimeric integral membrane proteins that contain an 
alpha chain and a beta chain which are expressed in a cell-type specific manner. They can 
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generate more than 20 various receptors that can bind ligands in the extracellular matrix 
such as collagen and fibronectin or mediate cell-cell adhesion. Signals transduced via 
integrins can regulate cell proliferation, activation, migration and homeostasis (Anderson 
et al., 2014). The integrin aIIb is expressed on platelets and can be used to mark blood 
clots in histologic sections. In this study, one-way ANOVA showed no significant 
differences (P > 0.05) between the three treatment groups in the amount of positive cells 
(Table 3.25). 
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Figure 3.36 Scoring relative staining intensity of immune cell infiltration 
for the three fluorochromes used for analysis 
Three different fluorochromes were used for analysis, including green, red, and 
far red fluorescence. Various scores were given to the photos based on the relative 
amount of stained cells. For some immune markers, CD4, PECAM -1, CD45, and the 
control IgG1 antibody the Alexa-488 dye was used in the green channel. For other 
immune markers, CD3, E-selectin, CD19, and IgG2b the Alexa546 red channel was used 
for analysis. Finally, the Alexa-633 dye in the far red channel (but printed in blue) was 
used for the rest of immune markers, including CD8, ICAM- 1, Integrin αllb, and the 
IgG2a control. Panel A shows examples corresponding to the scoring system for different 
photos stained with Alexa-488 (green). Panel B shows examples of the scores for 
different photos stained with Alexa-546 (red). Panel C shows examples of the scoring 
system for photos from sections stained with Alexa-633 (blue). 
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Figure 3.37 B16-Bl6 tumours were stained with control normal mouse 
IgG1, normal mouse IgG2b, and normal rat IgG2a 
Control immunoglobulins including normal mouse IgG1, normal mouse IgG2b, 
and normal rat IgG2a were used to determine the level of background staining in the 
sections. Eight fields were imaged (5 peripheral and 3 central) using an Olympus IX3 
fluorescence microscope set with a long exposure time to maximize detection of signal. 
The sections were stained with a normal mouse IgG1-Alexa-488 conjugate (detected in 
the green channel) a normal mouse IgG2b-Alexa-46 conjugate (detected in the red 
channel) and a normal mouse IgG2a-Alexa-633 conjugate (detected in the far red 
channel, but coloured blue) and a representative section is shown for each condition in 
Panel A (the Bar represents 100 µm). The relative intensity for the sections stained with 
the IgG1 and IgG2 control antibodies was determined and a mean and standard deviation 
determined for each condition and showed in Panel B. These results showed no 
significant differences (P > 0.05) between the three treatment groups using one-way 
ANOVA for each of the control antibodies.  
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Figure 3.38 B16-Bl6 tumours were stained for T cell markers CD4, 
CD3, and CD8 
Tissue sections were stained for T cell immune markers including CD4, CD3, and 
CD8. Eight fields were imaged (5 peripheral and 3 central) using an Olympus IX3 
fluorescence microscope to detect stained cells. The sections were stained with an anti-
CD4-Alexa-488 conjugate (detected in the green channel), an anti-CD3-Alexa-546 
conjugate (detected in the red channel), and an anti-CD8-Alexa-633 conjugate (detected 
in the far red channel, but coloured blue) and a representative section is shown for each 
condition in Panel A. The relative intensity for the sections stained with the anti-CD4, 
anti-CD3, and anti-CD8 antibodies was determined and a mean and standard deviation 
determined for each condition and is shown in Panel B. These results showed no 
significant differences (P > 0.05) between the three treatment groups using one-way 
ANOVA for each of the control antibodies.  
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Figure 3.39 B16-Bl6 tumours were evaluated for PECAM-1, E-selectin, 
and ICAM-1 expression 
Endothelial cell markers such as PECAM-1, E-selectin, and ICAM-1 were used 
for histochemical analysis of the mouse tissues. Eight fields were imaged (5 peripheral 
and 3 central) using an Olympus IX3 fluorescence microscope to detect stained cells. The 
sections were stained with an anti-PECAM-1-Alexa-488 conjugate (detected in the green 
channel), an anti-E-selectin-Alexa-546 conjugate (detected in the red channel), and an 
anti-ICAM-1-Alexa-633 conjugate (detected in the far red channel, but coloured blue) 
and a representative section is shown for each condition in Panel A. The relative intensity 
for the sections stained with the anti-PECAM-1, anti-E-selectin, and anti-ICAM-1 
antibodies was determined and a mean and standard deviation determined for each 
condition and is shown in Panel B. These results showed no significant differences (P > 
0.05) between the three treatment groups using one-way ANOVA for each of the control 
antibodies.  
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Figure 3.40 B16-Bl6 tumours were evaluated through CD45, CD19, and 
Integrin αllb 
Immune markers such as the common leukocyte marker CD45, the B cell marker 
CD19, and the platelet marker Integrin αllb were used for histochemical analysis of the 
mouse tissues. Eight fields were imaged (5 peripheral and 3 central) using an Olympus 
IX3 fluorescence microscope to detect stained cells. The sections were stained with an 
anti-CD45-Alexa-488 conjugate (detected in the green channel), an anti-CD19-Alexa-546 
conjugate (detected in the red channel), and an anti-integrin αIIb-Alexa-633 conjugate 
(detected in the far red channel, but coloured blue) and a representative section is shown 
for each condition in Panel A. The relative intensity for the sections stained with the anti-
CD45, anti-CD19, and anti- integrin αIIb antibodies was determined and a mean and 
standard deviation determined for each condition and is shown in Panel B. These results 
showed no significant differences (P > 0.05) between the three treatment groups using 
one-way ANOVA for each of the control antibodies.  
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3.4 Discussion 
3.4.1 The effect of U. tomentosa extract on tumour weight and size in 
animal models  
The ability of U. tomentosa extracts to inhibit the growth of tumours in vivo 
was tested by measuring the impact on tumours formed by B16/BL6 cells injected into 
C57BL/6 mice. This experimental model was chosen because the B16-BL6 cells are 
syngeneic with the C57BL/6 mice, which allows tumour growth to be measured in the 
presence of a normal immune system. This was considered to be important because 
treatment with U. tomentosa extracts has been shown to modulate the immune system, 
which might be important for modulating tumour growth.  
Two animal experiments were performed using a total of 50 male C57BL/6 
mice all of which had been injected with 105 B16-BL6 cells to establish tumours. For 
each experiment, the mice were divided into 5 groups, each containing 5 mice. The 5 
groups included: the control group that were not treated with U. tomentosa; a group 
treated with the ethanol extract of U. tomentosa (resuspended in PBS, pH 7.4) by intra-
peritoneal injection; a group treated with the ethanol extract of U. tomentosa by direct 
injection into the tumour; a group treated with the PBS extract of U. tomentosa by 
intra-peritoneal injection; and, a group treated with the PBS extract by direct injection 
into the tumour. For treatments, individual mice were each injected with 100 μl of 200 
μg/ml ethanol extract or PBS extract twice per week, starting 3 or 4 days after 
injection of the tumour cells, using intraperitoneal or intratumour injections. The mice 
were sacrificed approximately 18 days after injection of the tumour cells and the 
tumours excised and measured for weight and diameter.  
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Results showed that treatment with U. tomentosa extract caused a significant 
decrease in the tumour weight and tumour size although effect on the tumour size was 
less impacted. In some control tumours, there appeared to be more blood vessels 
apparent and more significant bleeding during necropsy, which could potentially be 
associated with tumour invasion and migration from the primary. However, no overt 
metastases were found during the post-mortem examination of the control or U. 
tomentosa-treated mice. All U. tomentosa treatment groups showed a significant 
decrease in tumor weight and tumour size compared to control-treated animals. 
However, there were no significant differences in tumour weight or size between the 
different treatment groups which means there was no difference in the effectiveness of 
the treatment in vivo that depended on injection type (i.e. intra-peritoneal versus 
directly into the tumour) or the type of the extract (i.e. ethanol versus PBS extracts). 
This is somewhat different from the in vitro results which showed that the ethanol 
extract of U. tomentosa was significantly more effective than the PBS extract. The 
reason for this difference is not clear but could be related to potential differences in 
mechanism between in vitro and in vivo effectiveness of U. tomentosa. It is also 
possible that the difference might be related to the resuspension of lyophilized powder 
derived from the ethanol extract in PBS, pH 7.4, prior to injection into the mice. Since 
it was not advisable to inject relatively large volumes of ethanol into the mice, the 
extracts had to be resuspended in an aqueous buffer, which may not have been able to 
solubilize all of the bioactive components prior to injection. 
Similar results have been obtained in other studies that used U. tomentosa 
extract as an anticancer treatment in animal models. Pilarski et al. (2010) examined the 
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effect of U. tomentosa extract on mice injected with Lewis lung carcinoma cells. In 
this study, IC50 values were used in order to prepare different quantitative and 
qualitative oxindole alkaloid compositions. One of the preparations produced by these 
researchers was to extract the bark in water at 37 ° C. They found that animals treated 
with this preparation had a significant reduction in tumor growth in vivo (Pilarski et 
al., 2010).  
Fazio et al. (2008) examined the effect of a hydroethanolic extract of U. 
tomentosa against B16/BL6 cells in female C57BL/6 mice. They documented that 
individual mice treated with the U. tomentosa extract had a significant reduction in 
tumor growth and metastasis (Fazio et al., 2008).  Taken together, these results are 
strongly consistent with our findings that U. tomentosa extract significantly reduced the 
tumour weight and size in vivo. 
 
3.4.2 B16-BL6 tumours were analyzed using histochemical detection of 
Ki-67, Factor VIII, and TUNEL markers 
In the present research, tumour samples (n=29) were analyzed for proliferation 
(Ki-67 staining), angiogenesis (factor VIII staining), and apoptosis (TUNEL staining) 
markers. Specifically, the expression of the cell proliferation nuclear marker, the Ki-67 
antigen, was measured in tumours isolated from control mice or mice treated by intra-
peritoneal injection with U. tomentosa extracted with ethanol or PBS. The relative 
level of Ki-67 antigen staining was calculated from 8 fields per each tumour slide and 
then the average staining for animals within each group were determined. Results 
showed that the Ki-67 staining levels were significantly reduced in the U. tomentosa-
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treated groups compared to the control. This means that U. tomentosa caused a 
significant reduction in the proliferation index of B16-BL6 in vivo. It is interesting that 
there was no difference in tumour staining that depended on whether PBS or ethanol 
extracts of U. tomentosa were injected which is different from the in vitro results.  
Furthermore, factor VIII staining was used in this study to evaluate the 
presence of angiogenesis in B16-BL6 tumours. Angiogenesis is the creation of new 
blood vessels arising from pre-existing blood vessels, which is required to meet the 
metabolic requirements of the rapidly growing tumour. For example, it is responsible 
for supplying oxygen and nutrients to the cells, as well as removing the metabolic 
waste (Rajabi and Mousa, 2017). The results demonstrated that the level of factor VIII-
positive cells were significantly greater in tumours isolated from animals in the control 
group compared to tumours isolated from the U. tomentosa extract-treated groups. 
This suggests that U. tomentosa caused a significant reduction in angiogenesis and 
metastasis in vivo. There was no difference in the anti-angiogenic impact of U. 
tomentosa depending on whether the ethanol or PBS extract was used. It would be 
interesting to see if in vitro experiments would show that the ethanol and PBS extracts 
of U. tomentosa would have the same effect on the growth and migration of 
endothelial cell cultures. If the two extracts had the same effect, this would support the 
idea that U. tomentosa-specific effects on tumour growth in vivo was dependent on 
more than the direct effects of U. tomentosa on the viability of cancer cells in vivo. 
Additionally, the histological tumour sections were stained with the TUNEL 
assay in order to evaluate cell death. The number of TUNEL-positive cells was 
calculated on 8 randomly selected fields for each tumour section via the fluorescence 
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microscope. The present study indicated that the number of TUNEL-positive cells in 
the treated tumours was not significantly higher than the control tumours. This means a 
large number of TUNEL stained cells were found in all three groups. The duration of 
the experiment might be the reason for showing a large number of apoptotic cells, even 
in the control group. For example, large tumours formed by the fast growing B16-BL6 
tumours usually show relatively high levels of apoptosis due to the lack of oxygen or 
metabolites even in the absence of any treatment. In addition, the tumours were 
isolated at the end of the experiment when any treatment-dependent changes in cellular 
apoptosis might be less significant. For example, changes in the level of apoptosis 
could be more significant at earlier times during tumour growth when the tumours 
were small and when cell death in the untreated tumours would be expected to be 
lower allowing any effect from U. tomentosa treatment to be detected. Therefore, 
different results might have obtained if the level of apoptotic cells in the tumours was 
examined earlier in the life of the tumour. 
 
3.4.3 Immune infiltration into B16-BL6 tumours were studied through 
immune markers 
Extracts isolated from a wide range of plants has shown significant anticancer 
activities through different biological pathways, including immune system modulation. 
Varied types of immune cells are frequently involved in this process, particularly 
cytotoxic T cells, natural killer cells, and monocyte/macrophages. It has been 
documented that a number of medicinal plants, such as Uncaria tomentosa, 
Glycyrrhiza glabra, Camellia sinensis, Panax ginseng, Prunus armenaica, Arctium 
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lappa, Allium sativum, and Curcuma longa have the ability to both alter immune 
responses and treat breast cancer. Based on the results of various studies, these plants 
have been shown to have bioactive immunomodulatory compounds, such as ginsan, 
glabridin, quinic acid, ajoene, arctigenin, β-carotene, and epigallocatechin-3-gallate 
(Baraya et al., 2017). 
In the current research, several immune markers were used in order to 
determine if the U. tomentosa extracts were able to affect the immune response against 
B16-Bl6 cells as measured by immune infiltration into the tumours. These immune 
markers include, general leukocyte markers such as CD45, T cell markers including 
CD3, CD4, and CD8, the B cell marker CD19, monocyte markers including integrin 
αIIB and endothelial activation markers including PECAM -1, E-selectin, and ICAM - 
1. Results indicated that all immune markers did not show significant differences in 
the relative levels of these markers between the control group and the U. tomentosa-
treated groups. This indicates that the level of infiltrating immune cells is not 
significantly different, independent of U. tomentosa treatment. Since U. tomentosa has 
been shown to have effects on immune cell activation in some experiments it is not clear 
why no differences were detected in these tumor samples. Some possible explanations for 
this lack of effect could be related to the observation that B16-BL6 cell tumours are able 
to strongly activate immune infiltration which can overcome any treatment effects and 
that the tumours are examined very late in their development where the levels of immune 
infiltrates have stabilized to similar levels independent of treatment. However, it should 
be noted that there were differences in the relative staining of some of the markers, in 
particular the T cell markers, which indicate that there are small decreases (15-20%) in 
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the mean relative staining levels in tumours from U. tomentosa-treated mice (although the 
variation in staining levels among animals was relatively large and therefore these 
differences were not significant). Therefore, further studies and investigation is required 
to determine the mechanism of inhibiting B16-BL6 tumours in vivo by U. tomentosa 
extracts.  
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Chapter 4. General Conclusion 
4.1 Cancer and natural products 
Cancer is a collective term for diseases distinguished by the growth of abnormal 
cells with the possibility of invading or spreading to other organs (WHO, 2018a; NCI, 
2018). Cancer is the second leading cause of death in the world and statistics show that 
cancer caused 8.8 million deaths in 2015, which means that one in six deaths worldwide 
are caused by cancer. Cancer can have multiple anatomic and molecular subtypes that 
each need particular management plans (WHO, 2018a). The common treatments for 
cancer include surgery, chemotherapy, radiation therapy, hormone therapy, and targeted 
therapy. Each treatment is used according to the type of cancer and the stage of the 
cancer. Some cancer patients may only receive a single type of treatment. However, most 
patients receive a combination of treatments (NCI, 2017). These treatments often aim to 
cure the patient of cancer but are always directed at prolonging life and improving the 
patients’ quality of life (WHO, 2018a). 
Breast cancer is a frequent cancer among women. Every year, over 1.5 million 
women are affected by breast cancer. Furthermore, statistics indicated that approximately 
570,000 women died of breast cancer in 2015, which is about 15% of all cancer deaths 
for women (WHO, 2018b). The rate of deaths due to breast cancer has decreased over the 
last several years as earlier diagnosis and improved treatment protocols have been 
developed. However, many of the chemotherapy treatments recommended for women 
with breast cancer can be quite toxic and are associated with significant side effects 
including anemia, thrombocytopenia, neutropenia, immune dysfunction, gastrointestinal 
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complications, fatigue, nausea, and hair loss (Ewertz and Jensen, 2011; Narod et al, 
2015). The serious side effects associated with conventional treatments as well as their 
limitations in efficacy (Lonning et al., 2004; Carpenter and Miller, 2005; Ewertz and 
Jensen, 2011) have motivated researchers to examine the anticancer properties of natural 
products, including medicinal plants. Hence, studies on medicinal plants have gained 
more interest among the public since they are believed to be less toxic and more 
“natural”. It has also been found that a number of plant-derived drugs have 
pharmacological properties and several of these have been demonstrated to be effective 
agents to treat cancer and some have been shown to reduce the side effects of 
conventional cancer treatments (Araújo et al., 2012). Further, many of the current 
chemotherapy drugs, such as paclitaxel, doxorubicin, vinblastine, etoposide, and 
camptothecin have been derived from natural products (Cragg et al., 1997). 
 
4.2 Uncaria tomentosa extracts 
U. tomentosa (Rubiaceae) is a typical tropical rain forest plant, and is naturally 
dispersed throughout South and Central America, chiefly in Peru and Brazil. It has been 
traditionally used as a medicinal plant by South American indigenous people who have 
used it for a very long time in the treatment of a wide range of different ailments. In the 
search for new therapeutics, researchers have cataloged a large number of Amazonian 
plants in an attempt to find natural compounds with low toxicity and high efficacy. With 
this aim in mind, the history of U. tomentosa use is notable because it is has been used in 
traditional medicine to treat a variety of inflammation-related different diseases 
(Heitzman et al., 2005; Zhang et al., 2015). In addition, Araújo et al. (2012) have shown 
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that U. tomentosa can be used as an efficient adjuvant therapy for breast cancer. 
Furthermore, it has been demonstrated that treatment with extracts of U. tomentosa can 
decrease the side effects of chemotherapy in cancer patients; it decreases the neutropenia 
caused by chemotherapy and is also capable of restoring cellular DNA damage (Araújo et 
al., 2012), further supporting the idea that this plant has clinical therapeutic potential. 
 
4.3 Comparing the effects of U. tomentosa extracts between in vitro 
results and in vivo results 
In this research, we showed that treatment with U. tomentosa extracts can greatly 
inhibit the growth of the B16-BL6 and 4T1 cell lines, especially when the cells were 
treated with the 70% ethanol extract at the highest dose of 200 μg/ml using an MTT 
assay. In addition, the expression of the Ki-67 antigen was significantly decreased when 
cancer cells were treated with U. tomentosa extracted with 70% ethanol at 200 μg/ml in 
vitro. However, the treatment with U. tomentosa extracted with PBS showed a lower 
effect. On the other hand, the in vivo results indicated that treatment with U. tomentosa 
extracted with ethanol and PBS significantly reduced tumour weight and size in the 
treated groups compared to the control in the same manner. This means there were no 
significant effects or interactions between the types of extract used for treatment in vivo.  
Since U. tomentosa extracts significantly blocked Ki-67 expression in cell 
cultures, the level of Ki-67 staining was also determined in B16-BL6 tumours isolated 
from animals using histochemical analysis. The Ki-67 staining intensity showed a 
significant reduction in the tumours from animals that treated with U. tomentosa 
compared to the control animals in vivo. Interestingly, no significant difference was 
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found between the two treated groups (ethanol and PBS) in terms of the Ki-67 staining 
intensity. This is somewhat different from the in vitro results which showed that the 
ethanol extract of U. tomentosa was significantly more effective than the PBS extract. 
The reason for this difference is not clear but could be related to potential differences in 
mechanism between in vitro and in vivo effectiveness of U. tomentosa. It is also possible 
that the difference might be related to the resuspension of lyophilized powder derived 
from the ethanol extract in PBS, pH 7.4, prior to injection into the mice. Since it was not 
advisable to inject relatively large volumes of ethanol into the mice, the extracts had to be 
resuspended in an aqueous buffer, which may not have been able to solubilize all of the 
bioactive components prior to injection. 
In the laboratory, U. tomentosa extracted with ethanol greatly promoted cell death 
in both cancer cell lines at the highest dose of 200 μg/ml using the TUNEL assay. 
However, a lower effect was observed when cells were treated with U. tomentosa 
extracted with PBS. Similarity, a huge increase in the percentage of the apoptotic cells 
present in the sub-G1 peak was found after the treatment with U. tomentosa extracted 
with ethanol using flow cytometry. However, the treatment of 4T1 cells with U. 
tomentosa extracted with PBS showed a smaller increase in the number of apoptotic cells 
in the sub-G1. 
 Since U. tomentosa extracts induced significant DNA fragmentation in cell 
cultures, the level of TUNEL staining was determined in B16-BL6 tumours using 
histochemical analysis in vivo. The in vivo results showed that there were small 
differences between the treated groups and the control. However, these differences were 
not statistically significant. These results are somewhat different from the in vitro results. 
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The duration of the experiment might be the reason for showing a large number of 
apoptotic cells, even in the control group. For example, the fast growing B16-BL6 
tumours usually show relatively high levels of apoptosis due to the lack of oxygen or 
metabolites even in the absence of any treatment. In addition, the tumours were 
isolated at the end of the experiment when any treatment-dependent changes in cellular 
apoptosis might be less significant. For example, changes in the level of apoptosis 
could be more significant at earlier times during tumour growth when cell death in the 
untreated tumours would be expected to be lower allowing any effect from U. 
tomentosa treatment to be detected. Therefore, different results might have obtained if 
the level of apoptotic cells in the tumours was examined earlier in the life of the 
tumour. 
In terms of HPLC, ethanol and PBS extracts showed different amounts of 
alkaloids. Our results suggest that these differences correlate with cell apoptosis 
induction in vitro. However, the in vivo data suggest the possibility that other 
components of U. tomentosa might be involved in tumour growth in vivo. Further 
experiments are required to test the possibility.  
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4.4 Conclusion 
Cancer is a serious public health problem that is considered a major cause of 
death worldwide. Medicinal plants have been used by several communities over 
thousands of years to improve health and treat many disorders. Recently, there has been 
considerable interest in examining the properties of various medicinal plants in order to 
learn more about their possible pharmacological properties for the development of new 
anti-cancer drugs with a relative lack of non-specific toxicity. These studies concluded 
that U. tomentosa extracts were an effective treatment against the B16-BL6 and 4T1 
mouse cancer cell lines. The ethanol extract of U. tomentosa had a much higher 
inhibitory effect than the PBS extract in vitro. The results showed that U. tomentosa 
extracted with ethanol prevented the proliferation of both cell lines and caused significant 
morphological changes. The extract also has the ability to induce cell death in cancer 
cells; in particular, DNA fragmentation was significant in treated cancer cells. 
Furthermore, the flow cytometry showed a large percentage of apoptotic cells in the sub-
G1 peak.  
On the other hand, the in vivo results documented that U. tomentosa successfully 
reduced both the tumour weight and tumor size. However, biweekly injection of U. 
tomentosa extracts did not have a detectable negative impact on mouse health. There 
were no significant differences in mouse weight, in the treated groups compared to the 
control and no changes in mouse behaviour were noted. Interestingly, there were no 
significant differences in the anti-tumour effects between the ethanol and PBS extracts of 
U. tomentosa or between intraperitoneal or intratumour injection in vivo. Histochemical 
 194 
 
analysis of the B16-BL6 tumour tissues excised from the mice, showed that treatment 
with the plant extract inhibited the proliferation of B16-BL6 in vivo using ki67 staining. 
Cell death as identified by TUNEL staining in vivo showed very small differences 
between the treated groups and the control. All immune markers did not show significant 
differences among the treated groups and the control. Collectively, U. tomentosa showed 
promising results as anticancer agents both in vitro and in vivo that might ultimately be 
effective in treating patients with cancer. Further analysis is required to understand the 
mechanism of action and also to evaluate the potential complications from this treatment. 
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